ClinicalTrials.gg
CompletedNCT03135834Updated Aug 8, 2023Results posted

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

A Phase 3 interventional study of MenABCWY and Saline in Meningococcal Vaccine, sponsored by Pfizer. Completed at 75 sites in 4 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,610
Allocation
Randomized
Ages
10 Years to 25 Years
Sex
All
01

Study summary

This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studying safety and immunogenicity of a meningococcal pentavalent vaccine.

02

Conditions studied

  • Meningococcal Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject aged >=10 and \<26 years at the time of enrollment.
  • Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
  • Negative urine pregnancy test for all female subjects.
  • Subjects who have not received, or who have received no more than 1 prior dose within the past 4 years, of a vaccine containing 1 or more ACWY serogroup

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any meningococcal serogroup B or purely polysaccharide (nonconjugate) meningococcal vaccine.
  • Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
  • A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) therapy, or those receiving therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.
  • Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  • Current chronic use of systemic antibiotics.
  • Received any vaccines, drugs, or devices within 28 days before administration of the first study vaccination.
  • Any neuroinflammatory or condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,610 participants (actual)

Study arms

  • Experimental
    Group 1 (ACWY Naive subjects, MenABCWY/Saline)

    ACWY Naive subjects, MenABCWY/Saline

    Biological: MenABCWY · Biological: Saline

  • Experimental
    Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)

    ACWY Naive subjects, rLP2086/MenACWY-CRM

    Biological: rLP2086 · Biological: MenACWY-CRM

  • Experimental
    Group 3 (ACWY Experienced subjects, MenABCWY/Saline)

    ACWY Experienced subjects, MenABCWY/Saline

    Biological: MenABCWY · Biological: Saline

  • Experimental
    Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)

    ACWY Experienced subjects, rLP2086/MenACWY-CRM

    Biological: rLP2086 · Biological: MenACWY-CRM

Interventions

  • BiologicalMenABCWY

    N meningitidis group A, B, C, W, and Y vaccine

  • BiologicalSaline

    Placebo

  • BiologicalrLP2086

    Drug pages: MenB-FHbp vaccine · 4CMenB vaccine

    Bivalent recombinant lipoprotein 2086 vaccine

  • BiologicalMenACWY-CRM

    meningococcal group A, C, W-135, and Y conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Stage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>= LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome. Analysis for this outcome measure was planned for combined Group 2 and 4.

    Time frame: 1 month after Vaccination 2

  2. Stage1: Percentage of Participants With Fold Rise >=4 in hSBA for Each of the 4 Primary MenB Test Strains From Baseline to 1 Month After Vaccination 2 (Group 2 and 4 Combined)

    The 4-fold increase: a) participants with baseline hSBA titer below limit of detection (LOD or an hSBA titer \<1:4), response was defined as hSBA titer \>=1:16 or LLOQ (whichever titer is higher); b) Participants with baseline hSBA titer \>= LOD and \< LLOQ, response was defined as hSBA titer \>= 4 times the LLOQ; c) participants with baseline hSBA titer \>= LLOQ, response was defined as hSBA titer \>=4 times baseline titer. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Analysis for this outcome measure was planned for combined Group 2 and 4.

    Time frame: From Baseline (blood draw prior to Vaccination 1) to 1 month after Vaccination 2

  3. Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)

    Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: 7 days after Vaccination 1

  4. Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)

    Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: 7 days after Vaccination 2

  5. Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)

    Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, and joint pain were recorded by using an e-diary. Fever was defined as \>=38.0 degree Celsius (C) and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

    Time frame: 7 days after Vaccination 1

  6. Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)

    Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, and joint pain were recorded by using an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

    Time frame: 7 days after Vaccination 2

  7. Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)

    Time frame: 7 days after Vaccination 1

  8. Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)

    Time frame: 7 days after Vaccination 2

  9. Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: 30 days after Vaccination 1

  10. Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: 30 days after Vaccination 2

  11. Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: 30 days after any vaccination

  12. Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  13. Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.

    Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)

  14. Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1 (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.

    Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)

  15. Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 days after Vaccination 1

  16. Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 days after Vaccination 2

  17. Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 days after any vaccination

  18. Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  19. Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)

  20. Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1 (Group 2 and 4 Combined)

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)

  21. Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: 30 days after Vaccination 1

  22. Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: 30 days after Vaccination 2

  23. Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination (Group 2 and 4 Combined)

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: 30 days after any Vaccination

  24. Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  25. Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)

  26. Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Throughout the Stage 1 (Group 2 and 4)

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)

  27. Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: 30 days after Vaccination 1

  28. Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: 30 days after Vaccination 2

  29. Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: 30 days after any vaccination

  30. Stage1: Percentage of Participants With at Least 1 AE During Vaccination Phase (Group 2 and 4 Combined)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  31. Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1 (Group 2 and 4 Combined)

    Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

    Time frame: 30 minutes after Vaccination 1

  32. Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2 (Group 2 and 4 Combined)

    Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

    Time frame: 30 minutes after Vaccination 2

  33. Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  34. Stage2: Percentage of Participants With Local Reactions Within 7 Days After Booster Vaccination: Group 1 Through Group 4

    Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: 7 days after booster vaccination

  35. Stage2: Percentage of Participants With Systemic Events Within 7 Days After Booster Vaccination: Group 1 Through Group 4

    Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree Celsius (C) and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

    Time frame: 7 days after booster vaccination

  36. Stage2: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Booster Vaccination: Group 1 Through Group 4

    Time frame: 7 days after booster vaccination

  37. Stage2: Percentage of Participants With at Least 1 SAE During Booster Vaccination Phase: Group 1 Through Group 4

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. SAE of "pregnancy" for one participant during the booster vaccination phase was recorded erroneously and hence it was included in results of Group 4.

    Time frame: Booster vaccination phase: From booster vaccination through 1 month after booster vaccination

  38. Stage2: Percentage of Participants With at Least 1 SAE During the Booster Follow-up Phase: Group 1 Through Group 4

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: Booster follow-up phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)

  39. Stage2: Percentage of Participants With at Least 1 SAE Throughout Booster Phase: Group 1 Through Group 4

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. SAE of "pregnancy" for one participant during the booster vaccination phase was recorded erroneously and hence it was reported in result of outcome measure 37 for Group 4. Subsequently correction was made by the trial site and not included in subsequent phase/results. Hence, that 1 participant is not included in results of Group 4 here.

    Time frame: Throughout Booster phase: From booster vaccination through 6 months after booster vaccination

  40. Stage2: Percentage of Participants With at Least 1 Medically Attended AE During Booster Vaccination Phase: Group 1 Through Group 4

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Booster vaccination phase: From booster vaccination through 1 month after booster vaccination

  41. Stage2: Percentage of Participants With at Least 1 Medically Attended AE During the Booster Follow-up Phase: Group 1 Through Group 4

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Booster Follow-up Phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)

  42. Stage2: Percentage of Participants With at Least 1 Medically Attended AE Throughout Booster Phase: Group 1 Through Group 4

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Throughout Booster Phase: From booster vaccination through 6 months after booster vaccination

  43. Stage2: Percentage of Participants With at Least 1 NDCMC During Booster Vaccination Phase: Group 1 Through Group 4

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination

  44. Stage2: Percentage of Participants With at Least 1 NDCMC During the Booster Follow-up Phase: Group 1 Through Group 4

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Booster Follow-up Phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)

  45. Stage2: Percentage of Participants With at Least 1 NDCMC Throughout Booster Phase: Group 1 Through Group 4

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Throughout Booster Phase: From booster vaccination through 6 months after booster vaccination

  46. Stage2: Percentage of Participants With at Least 1 AE During Booster Vaccination Phase: Group 1 Through Group 4

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination

  47. Stage2: Percentage of Participants With at Least 1 Immediate AE After Booster Vaccination: Group 1 Through Group 4

    Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

    Time frame: 30 minutes after booster vaccination

  48. Stage2: Number of Participants Who Missed School/Work Due to AE After Booster Vaccination: Group 1 Through Group 4

    Time frame: Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination

Secondary outcomes

  1. Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>= LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).

    Time frame: 1 month after Vaccination 2

  2. Stage1: Percentage of Participants With hSBA Titer Level >= 1:4, >= 1:8, >= 1:16, >= 1:32, >= 1:64, >= 1:128 for All 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>= 1:4, \>= 1:8, \>= 1:16, \>= 1:32, \>= 1:64, \>= 1:128 for all 4 primary MenB test strains was reported in this outcome measure. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).

    Time frame: 1 month after Vaccination 2 (Vacc 2)

  3. Stage1: hSBA Geometric Mean Titers (GMTs) for All 4 Primary MenB Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)

    GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5 \* LLOQ for analysis. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).

    Time frame: 1 month after Vaccination 2 (Vacc 2)

  4. Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer greater than or equal to LLOQ for 10 Secondary MenB test strains combined (LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16) was reported in this outcome measure.

    Time frame: 1 month after Vaccination 2 (Vacc 2)

  5. Stage1: Percentage of Participants With hSBA Titer Level >= 1:4, >= 1:8, >= 1:16, >= 1:32, >= 1:64, >= 1:128 for Each of the 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>= 1:4, \>= 1:8, \>= 1:16, \>= 1:32, \>= 1:64, \>= 1:128 for each of the 10 secondary MenB test strains was reported in this outcome measure. 10 secondary MenB test strains were PMB3175 (A29), PMB3010 (A06), PMB824 (A12), PMB3040 (A07), PMB1672 (A15), PMB1989 (A19), PMB648 (B16), PMB866 (B09), PMB1256 (B03) and PMB431 (B15).

    Time frame: 1 month after Vaccination 2 (Vacc 2)

  6. Stage1: hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

    GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.

    Time frame: 1 month after Vaccination 2 (Vacc 2)

  7. Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=LLOQ for ACWY Test Strains 1 Month After the Vaccination 1: Groups 1, 2, 3 and 4

    Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.

    Time frame: 1 month after Vaccination 1

  8. Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for ACWY Test Strains 1 Month After the Vaccination 1: Groups 1, 2, 3 and 4

    Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.

    Time frame: 1 month after Vaccination 1

  9. Stage1: hSBA Geometric Mean Titers (GMTs) for ACWY Test Strains 1 Month After Vaccination 1: Groups 1, 2, 3 and 4

    GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.

    Time frame: 1 month after Vaccination 1

  10. Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or LLOQ, Whichever is Higher) for ACWY Test Strains 1 Month After the Vaccination 1 in Groups 2 and 4, and 1 Month After Vaccination 2 in Groups 1 and 3

    Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>= LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.

    Time frame: For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2

  11. Stage1: Percentage of Participants With MenA, MenC, MenW, and MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and, >=1:128 for ACWY Test Strains 1 Month After Vaccination 1 in Groups 2 and 4, and 1 Month After Vaccination 2 in Groups 1 and 3

    Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.

    Time frame: For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2

  12. Stage1: hSBA GMTs for ACWY Test Strains 1 Month After Vaccination 1 in Groups 2 and 4 and 1 Month After Vaccination 2 in Groups 1 and 3

    GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.

    Time frame: For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2

  13. Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

    Time frame: 1 month after Vaccination 2 (Vacc 2)

  14. Stage1: Percentage of Participants With >=4 Fold Rise in hSBA for 4 Primary MenB Strains and Composite Response (hSBA >=LLOQ for All 4 Primary MenB Strains Combined) From Baseline-1 Month After Vaccination 2 (Group 1 and 3 Combined;Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer greater than or equal to LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

    Time frame: Baseline to 1 month after Vaccination 2

  15. Stage1: Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for Each of the 4 Primary MenB Test Strains From 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 for all 4 primary MenB test strains was reported in this outcome measure.

    Time frame: 1 month after Vaccination 2

  16. Stage1: hSBA GMTs for Each of the 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

    GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ =1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.

    Time frame: 1 month after Vaccination 2

  17. Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW and hSBA-MenY Titers >=1:8 (or LLOQ) for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4

    Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.

    Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]

  18. Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4

    Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>= :8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.

    Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]

  19. Stage1: hSBA GMTs for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4

    GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains. Titers below the LLOQ were set to 0.5\*LLOQ for analysis. Confidence intervals were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the concentrations, or the mean of the ratio.

    Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]

  20. Stage1: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

    Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]

  21. Stage1: Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for Each of the 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 for each of the 4 primary MenB test strains was reported in this outcome measure.

    Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]

  22. Stage1: hSBA GMTs for Each of the 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

    GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ =1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5\*LLOQ for analysis. CIs were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the hSBA titers.

    Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]

  23. Stage2: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or LLOQ if Higher) for ACWY Test Strains During Persistence Phase: Groups 1, 2, 3 and 4

    Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY Test Strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.

    Time frame: 12, 24, 36 and 48 months after Vaccination 2 (Vacc 2)

  24. Stage2: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains During Persistence Phase (Group 1 and 3 Combined; Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

    Time frame: 12, 24, 36 and 48 months after Vaccination 2 (Vacc 2)

  25. Stage2: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or >=LLOQ if Higher) for ACWY Test Strains 1 Month After Booster Vaccination: Groups 1 and 3 (Separately)

    Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure. Analysis was planned for Group 1 and 3 separately.

    Time frame: 1 month after booster vaccination

  26. Stage2: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains 1 Month After Booster Vaccination (Group 1 and 3 Combined; Group 2 and 4 Combined)

    Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

    Time frame: 1 month after booster vaccination

  27. Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1: Group 1 and Group 3

    Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: 7 days after Vaccination 1 (Vacc 1)

  28. Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2: Group 1 and Group 3

    Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: 7 days after Vaccination 2 (Vacc 2)

  29. Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1: Group 1 and Group 3

    Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

    Time frame: 7 days after Vaccination 1 (Vacc 1)

  30. Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2: Group 1 and Group 3

    Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

    Time frame: 7 days after Vaccination 2 (Vacc 2)

  31. Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 1: Group 1 and Group 3

    Time frame: 30 days after Vaccination 1

  32. Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 2: Group 1 and Group 3

    Time frame: 30 days after Vaccination 2

  33. Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 1: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: 30 days after Vaccination 1

  34. Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 2: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: 30 days after Vaccination 2

  35. Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: 30 days after any vaccination

  36. Stage1: Percentage of Participants With at Least 1 SAE During the Vaccination Phase: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  37. Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.

    Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)

  38. Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.

    Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)

  39. Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1: Group 1 and Group 3

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 days after vaccination 1

  40. Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2: Group 1 and Group 3

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 days after vaccination 2

  41. Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination: Group 1 and Group 3

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 days after any vaccination

  42. Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase: Group 1 and Group 3

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  43. Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase: Group 1 and Group 3

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)

  44. Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1: Group 1 and Group 3

    Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)

  45. Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 1: Group 1 and Group 3

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: 30 days after vaccination 1

  46. Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 2: Group 1 and Group 3

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: 30 days after vaccination 2

  47. Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Any Vaccination: Group 1 and Group 3

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: 30 days after any vaccination

  48. Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Vaccination Phase: Group 1 and Group 3

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  49. Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Follow-up Phase: Group 1 and Group 3

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)

  50. Stage1: Percentage of Participants With at Least 1 NDCMC Throughout the Stage 1: Group 1 and Group 3

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)

  51. Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: 30 days after vaccination 1

  52. Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: 30 days after vaccination 2

  53. Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination Any Vaccination: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: 30 days after any vaccination

  54. Stage1: Percentage of Participants With at Least 1 AE During the Stage 1 Vaccination Phase: Group 1 and Group 3

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

  55. Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1: Group 1 and Group 3

    Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

    Time frame: 30 minutes after Vaccination 1

  56. Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2: Group 1 and Group 3

    Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

    Time frame: 30 minutes after Vaccination 2

  57. Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase: Group 1 and Group 3

    Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)

07

Results

Posted Aug 8, 2023
Limitations and caveats
SAE of "pregnancy" for 1 participant during booster vaccination phase (Stage 2) was recorded erroneously and was reported in result of outcome measure 37. One participant had an SAE which was recorded after 8 months of vaccination 2 and one participant had an SAE after 15 months of Vaccination 2. This time period did not present Stage 1 or Stage 2. Hence, it was not included in related outcome measure summary. However, these participants were included in adverse events module for Stage 1.

Participant flow

The study had 2 stages: 1 and 2. Study was conducted at 68 sites in Stage 1, with 39 of those sites participating in Stage 2. Participants were randomized as ACWY-naive and ACWY-experienced (received 1 prior dose of a vaccine containing 1 or more ACWY groups greater than or equal to \[\>=\] 4 years prior to randomization).

Stage 1
Participant flow — Stage 1
MilestoneGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Started272537272529
Vaccination 1 at month 0272534271523
Vaccination 2 at month 6242469244477
Completed233462232463
Not completed39754066
Withdrew: Adverse event1221
Withdrew: Death1000
Withdrew: Lost to follow-up17242138
Withdrew: No longer met eligibility criteria1625
Withdrew: Other0210
Withdrew: Physician decision0100
Withdrew: Pregnancy0424
Withdrew: Protocol violation1121
Withdrew: Withdrawal by parent/guardian21021
Withdrew: Withdrawal by subject1622710
Withdrew: Randomized but not vaccinated0316
Stage 2
Participant flow — Stage 2
MilestoneGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Started1146510173
Antibody persistence: blood draw month18114635323
Antibody persistence: blood draw month 30104619671
Antibody persistence: blood draw month 4297559768
Received booster vaccination67407758
Completed67387758
Not completed47272415
Withdrew: Lost to follow-up0100
Withdrew: Withdrawal by subject0100
Withdrew: Withdrawn before booster vaccination46242415
Withdrew: Did not receive booster vaccination1100

Outcome measures

PrimaryStage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>= LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome. Analysis for this outcome measure was planned for combined Group 2 and 4.

Time frame:
1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)74.3 (71.2 to 77.3)
PrimaryStage1: Percentage of Participants With Fold Rise >=4 in hSBA for Each of the 4 Primary MenB Test Strains From Baseline to 1 Month After Vaccination 2 (Group 2 and 4 Combined)

The 4-fold increase: a) participants with baseline hSBA titer below limit of detection (LOD or an hSBA titer \<1:4), response was defined as hSBA titer \>=1:16 or LLOQ (whichever titer is higher); b) Participants with baseline hSBA titer \>= LOD and \< LLOQ, response was defined as hSBA titer \>= 4 times the LLOQ; c) participants with baseline hSBA titer \>= LLOQ, response was defined as hSBA titer \>=4 times baseline titer. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Analysis for this outcome measure was planned for combined Group 2 and 4.

Time frame:
From Baseline (blood draw prior to Vaccination 1) to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Fold Rise >=4 in hSBA for Each of the 4 Primary MenB Test Strains From Baseline to 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22)73.8 (70.6 to 76.7)
PMB2001 (A56)95.0 (93.3 to 96.4)
PMB2948 (B24)67.4 (64.1 to 70.6)
PMB2707 (B44)86.4 (83.9 to 88.6)
PrimaryStage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)

Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
7 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Redness: Any16.9 (14.6 to 19.3)
Redness: Mild6.8 (5.3 to 8.5)
Redness: Moderate8.0 (6.5 to 9.9)
Redness: Severe2.0 (1.2 to 3.1)
Swelling: Any17.0 (14.7 to 19.4)
Swelling: Mild9.8 (8.0 to 11.7)
Swelling: Moderate6.9 (5.4 to 8.6)
Swelling: Severe0.3 (0.1 to 0.8)
Pain at injection site: Any85.0 (82.6 to 87.1)
Pain at injection site: Mild41.2 (38.2 to 44.2)
Pain at injection site: Moderate39.1 (36.1 to 42.1)
Pain at injection site: Severe4.7 (3.5 to 6.2)
PrimaryStage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)

Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
7 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Redness: Any14.7 (12.5 to 17.2)
Redness: Mild5.2 (3.8 to 6.9)
Redness: Moderate8.4 (6.7 to 10.4)
Redness: Severe1.1 (0.5 to 2.0)
Swelling: Any14.3 (12.1 to 16.7)
Swelling: Mild6.4 (4.9 to 8.2)
Swelling: Moderate7.5 (5.9 to 9.4)
Swelling: Severe0.3 (0.1 to 1.0)
Pain at injection site: Any82.2 (79.5 to 84.6)
Pain at injection site: Mild38.9 (35.7 to 42.1)
Pain at injection site: Moderate37.9 (34.7 to 41.1)
Pain at injection site: Severe5.4 (4.0 to 7.1)
PrimaryStage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)

Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, and joint pain were recorded by using an e-diary. Fever was defined as \>=38.0 degree Celsius (C) and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

Time frame:
7 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Fever: >= 38.0 degree C6.7 (5.3 to 8.4)
Fever: 38.0 to 38.4 degree C4.0 (2.9 to 5.4)
Fever: 38.5 to 38.9 degree C2.1 (1.3 to 3.2)
Fever: 39.0 to 40.0 degree C0.6 (0.2 to 1.2)
Fever: > 40.0 degree C0.0 (0.0 to 0.4)
Fatigue: Any51.9 (48.8 to 55.0)
Fatigue: Mild25.4 (22.8 to 28.1)
Fatigue: Moderate23.7 (21.1 to 26.4)
Fatigue: Severe2.9 (1.9 to 4.1)
Headache: Any46.5 (43.4 to 49.5)
Headache: Mild25.1 (22.5 to 27.8)
Headache: Moderate19.0 (16.6 to 21.5)
Headache: Severe2.4 (1.6 to 3.5)
Chills: Any18.5 (16.2 to 21.0)
Chills: Mild11.5 (9.6 to 13.6)
Chills: Moderate5.7 (4.4 to 7.3)
Chills: Severe1.2 (0.7 to 2.1)
Vomiting: Any3.7 (2.7 to 5.1)
Vomiting: Mild2.9 (1.9 to 4.1)
Vomiting: Moderate0.9 (0.4 to 1.6)
Vomiting: severe0.0 (0.0 to 0.4)
Diarrhea: Any14.1 (12.0 to 16.3)
Diarrhea: Mild10.7 (8.9 to 12.8)
Diarrhea: Moderate3.3 (2.3 to 4.5)
Diarrhea: Severe0.1 (0.0 to 0.5)
Muscle pain: Any28.4 (25.7 to 31.3)
Muscle pain: Mild15.8 (13.6 to 18.2)
Muscle pain: Moderate11.6 (9.7 to 13.7)
Muscle pain: Severe1.1 (0.5 to 1.9)
Joint pain: Any19.6 (17.3 to 22.2)
Joint pain: Mild10.2 (8.5 to 12.3)
Joint pain: Moderate8.6 (7.0 to 10.5)
Joint pain: Severe0.8 (0.3 to 1.5)
PrimaryStage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)

Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, and joint pain were recorded by using an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

Time frame:
7 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Fever: >= 38.0 degree C3.2 (2.2 to 4.6)
Fever: 38.0 to 38.4 degree C1.9 (1.1 to 3.0)
Fever: 38.5 to 38.9 degree C0.7 (0.2 to 1.4)
Fever: 39.0 to 40.0 degree C0.7 (0.2 to 1.4)
Fever: > 40.0 degree C0.0 (0.0 to 0.4)
Fatigue: Any45.2 (41.9 to 48.5)
Fatigue: Mild23.0 (20.3 to 25.9)
Fatigue: Moderate19.2 (16.6 to 21.9)
Fatigue: Severe3.0 (2.0 to 4.3)
Headache: Any41.6 (38.4 to 44.9)
Headache: Mild23.1 (20.4 to 26.0)
Headache: Moderate16.5 (14.1 to 19.1)
Headache: Severe2.0 (1.2 to 3.1)
Chills: Any18.5 (16.0 to 21.2)
Chills: Mild11.6 (9.6 to 13.9)
Chills: Moderate6.2 (4.7 to 8.0)
Chills: Severe0.7 (0.2 to 1.4)
Vomiting: Any2.8 (1.8 to 4.1)
Vomiting: Mild2.0 (1.2 to 3.1)
Vomiting: Moderate0.8 (0.3 to 1.6)
Vomiting: Severe0.0 (0.0 to 0.4)
Diarrhea: Any10.6 (8.7 to 12.8)
Diarrhea: Mild7.6 (6.0 to 9.6)
Diarrhea: Moderate2.5 (1.6 to 3.8)
Diarrhea: Severe0.4 (0.1 to 1.1)
Muscle pain: Any21.4 (18.7 to 24.2)
Muscle pain: Mild11.5 (9.5 to 13.8)
Muscle pain: Moderate7.8 (6.1 to 9.7)
Muscle pain: Severe2.1 (1.3 to 3.3)
Joint pain: Any18.7 (16.2 to 21.4)
Joint pain: Mild11.2 (9.2 to 13.4)
Joint pain: Moderate6.5 (5.0 to 8.3)
Joint pain: Severe1.0 (0.5 to 1.9)
PrimaryStage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)
Time frame:
7 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)18.6 (16.3 to 21.1)
PrimaryStage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)
Time frame:
7 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)14.4 (12.2 to 16.9)
PrimaryStage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)0.0 (0.0 to 0.3)
PrimaryStage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)0.0 (0.0 to 0.4)
PrimaryStage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
30 days after any vaccination
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)0.0 (0.0 to 0.3)
PrimaryStage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)0.8 (0.3 to 1.5)
PrimaryStage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.

Time frame:
Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)0.5 (0.2 to 1.2)
PrimaryStage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1 (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.

Time frame:
Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1 (Group 2 and 4 Combined)1.3 (0.7 to 2.2)
PrimaryStage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)6.3 (4.9 to 8.0)
PrimaryStage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)8.8 (7.0 to 10.8)
PrimaryStage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 days after any vaccination
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)13.3 (11.3 to 15.5)
PrimaryStage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)26.7 (24.0 to 29.5)
PrimaryStage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)16.6 (14.3 to 19.2)
PrimaryStage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1 (Group 2 and 4 Combined)

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1 (Group 2 and 4 Combined)33.7 (30.8 to 36.6)
PrimaryStage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)0.3 (0.1 to 0.8)
PrimaryStage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)0.2 (0.0 to 0.8)
PrimaryStage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination (Group 2 and 4 Combined)

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
30 days after any Vaccination
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination (Group 2 and 4 Combined)0.5 (0.2 to 1.1)
PrimaryStage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)0.8 (0.3 to 1.5)
PrimaryStage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)0.3 (0.1 to 0.9)
PrimaryStage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Throughout the Stage 1 (Group 2 and 4)

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Throughout the Stage 1 (Group 2 and 4)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Throughout the Stage 1 (Group 2 and 4)0.9 (0.5 to 1.7)
PrimaryStage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)13.8 (11.8 to 16.0)
PrimaryStage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)14.7 (12.5 to 17.1)
PrimaryStage1: Percentage of Participants With at Least 1 AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
30 days after any vaccination
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)24.1 (21.6 to 26.8)
PrimaryStage1: Percentage of Participants With at Least 1 AE During Vaccination Phase (Group 2 and 4 Combined)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 AE During Vaccination Phase (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 AE During Vaccination Phase (Group 2 and 4 Combined)40.7 (37.7 to 43.7)
PrimaryStage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1 (Group 2 and 4 Combined)

Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

Time frame:
30 minutes after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1 (Group 2 and 4 Combined)0.9 (0.4 to 1.6)
PrimaryStage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2 (Group 2 and 4 Combined)

Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

Time frame:
30 minutes after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2 (Group 2 and 4 Combined)0.3 (0.1 to 0.9)
PrimaryStage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Count of participants · Participants
Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
ParticipantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)171
PrimaryStage2: Percentage of Participants With Local Reactions Within 7 Days After Booster Vaccination: Group 1 Through Group 4

Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
7 days after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With Local Reactions Within 7 Days After Booster Vaccination: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Redness: Any13.6 (6.0 to 25.0)28.6 (14.6 to 46.3)21.6 (12.9 to 32.7)25.5 (14.7 to 39.0)
Redness: Mild5.1 (1.1 to 14.1)11.4 (3.2 to 26.7)9.5 (3.9 to 18.5)14.5 (6.5 to 26.7)
Redness: Moderate3.4 (0.4 to 11.7)11.4 (3.2 to 26.7)8.1 (3.0 to 16.8)9.1 (3.0 to 20.0)
Redness: Severe5.1 (1.1 to 14.1)5.7 (0.7 to 19.2)4.1 (0.8 to 11.4)1.8 (0.0 to 9.7)
Swelling: Any18.6 (9.7 to 30.9)25.7 (12.5 to 43.3)18.9 (10.7 to 29.7)18.2 (9.1 to 30.9)
Swelling: Mild10.2 (3.8 to 20.8)11.4 (3.2 to 26.7)6.8 (2.2 to 15.1)9.1 (3.0 to 20.0)
Swelling: Moderate8.5 (2.8 to 18.7)11.4 (3.2 to 26.7)12.2 (5.7 to 21.8)7.3 (2.0 to 17.6)
Swelling: Severe0.0 (0.0 to 6.1)2.9 (0.1 to 14.9)0.0 (0.0 to 4.9)1.8 (0.0 to 9.7)
Pain at injection site: Any79.3 (66.6 to 88.8)85.7 (69.7 to 95.2)85.1 (75.0 to 92.3)85.5 (73.3 to 93.5)
Pain at injection site: Mild41.4 (28.6 to 55.1)25.7 (12.5 to 43.3)36.5 (25.6 to 48.5)47.3 (33.7 to 61.2)
Pain at injection site: Moderate36.2 (24.0 to 49.9)45.7 (28.8 to 63.4)47.3 (35.6 to 59.3)38.2 (25.4 to 52.3)
Pain at injection site: Severe1.7 (0.0 to 9.2)14.3 (4.8 to 30.3)1.4 (0.0 to 7.3)0.0 (0.0 to 6.5)
PrimaryStage2: Percentage of Participants With Systemic Events Within 7 Days After Booster Vaccination: Group 1 Through Group 4

Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree Celsius (C) and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

Time frame:
7 days after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With Systemic Events Within 7 Days After Booster Vaccination: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Fever: >= 38.0 degree C5.0 (1.0 to 13.9)2.6 (0.1 to 13.5)0.0 (0.0 to 4.7)1.8 (0.0 to 9.6)
Fever: 38.0 to 38.4 degree C1.7 (0.0 to 8.9)0.0 (0.0 to 9.0)0.0 (0.0 to 4.7)1.8 (0.0 to 9.6)
Fever: 38.4 to 38.9 degree C0.0 (0.0 to 6.0)2.6 (0.1 to 13.5)0.0 (0.0 to 4.7)0.0 (0.0 to 6.4)
Fever: 38.9 to 40.0 degree C3.3 (0.4 to 11.5)0.0 (0.0 to 9.0)0.0 (0.0 to 4.7)0.0 (0.0 to 6.4)
Fever: > 40.0 degree C0.0 (0.0 to 6.0)0.0 (0.0 to 9.0)0.0 (0.0 to 4.7)0.0 (0.0 to 6.4)
Fatigue: Any46.7 (33.7 to 60.0)61.5 (44.6 to 76.6)61.8 (50.0 to 72.8)66.1 (52.2 to 78.2)
Fatigue: Mild25.0 (14.7 to 37.9)25.6 (13.0 to 42.1)50.0 (38.3 to 61.7)37.5 (24.9 to 51.5)
Fatigue: Moderate21.7 (12.1 to 34.2)30.8 (17.0 to 47.6)10.5 (4.7 to 19.7)23.2 (13.0 to 36.4)
Fatigue: Severe0.0 (0.0 to 6.0)5.1 (0.6 to 17.3)1.3 (0.0 to 7.1)5.4 (1.1 to 14.9)
Headache: Any36.7 (24.6 to 50.1)53.8 (37.2 to 69.9)46.1 (34.5 to 57.9)55.4 (41.5 to 68.7)
Headache: Mild25.0 (14.7 to 37.9)20.5 (9.3 to 36.5)34.2 (23.7 to 46.0)39.3 (26.5 to 53.2)
Headache: Moderate8.3 (2.8 to 18.4)28.2 (15.0 to 44.9)10.5 (4.7 to 19.7)14.3 (6.4 to 26.2)
Headache: Severe3.3 (0.4 to 11.5)5.1 (0.6 to 17.3)1.3 (0.0 to 7.1)1.8 (0.0 to 9.6)
Chills: Any10.0 (3.8 to 20.5)17.9 (7.5 to 33.5)18.4 (10.5 to 29.0)14.3 (6.4 to 26.2)
Chills: Mild10.0 (3.8 to 20.5)12.8 (4.3 to 27.4)15.8 (8.4 to 26.0)12.5 (5.2 to 24.1)
Chills: Moderate0.0 (0.0 to 6.0)5.1 (0.6 to 17.3)2.6 (0.3 to 9.2)0.0 (0.0 to 6.4)
Chills: Severe0.0 (0.0 to 6.0)0.0 (0.0 to 9.0)0.0 (0.0 to 4.7)1.8 (0.0 to 9.6)
Vomiting: Any3.3 (0.4 to 11.5)0.0 (0.0 to 9.0)2.6 (0.3 to 9.2)1.8 (0.0 to 9.6)
Vomiting: Mild1.7 (0.0 to 8.9)0.0 (0.0 to 9.0)1.3 (0.0 to 7.1)1.8 (0.0 to 9.6)
Vomiting: Moderate1.7 (0.0 to 8.9)0.0 (0.0 to 9.0)1.3 (0.0 to 7.1)0.0 (0.0 to 6.4)
Vomiting: severe0.0 (0.0 to 6.0)0.0 (0.0 to 9.0)0.0 (0.0 to 4.7)0.0 (0.0 to 6.4)
Diarrhea: Any5.0 (1.0 to 13.9)10.3 (2.9 to 24.2)9.2 (3.8 to 18.1)12.5 (5.2 to 24.1)
Diarrhea: Mild5.0 (1.0 to 13.9)7.7 (1.6 to 20.9)7.9 (3.0 to 16.4)7.1 (2.0 to 17.3)
Diarrhea: Moderate0.0 (0.0 to 6.0)2.6 (0.1 to 13.5)1.3 (0.0 to 7.1)5.4 (1.1 to 14.9)
Diarrhea: Severe0.0 (0.0 to 6.0)0.0 (0.0 to 9.0)0.0 (0.0 to 4.7)0.0 (0.0 to 6.4)
Muscle Pain: Any18.3 (9.5 to 30.4)30.8 (17.0 to 47.6)31.6 (21.4 to 43.3)23.2 (13.0 to 36.4)
Muscle pain: Mild13.3 (5.9 to 24.6)10.3 (2.9 to 24.2)22.4 (13.6 to 33.4)19.6 (10.2 to 32.4)
Muscle pain: Moderate5.0 (1.0 to 13.9)12.8 (4.3 to 27.4)7.9 (3.0 to 16.4)3.6 (0.4 to 12.3)
Muscle pain: Severe0.0 (0.0 to 6.0)7.7 (1.6 to 20.9)1.3 (0.0 to 7.1)0.0 (0.0 to 6.4)
Joint Pain: Any18.3 (9.5 to 30.4)25.6 (13.0 to 42.1)21.1 (12.5 to 31.9)16.1 (7.6 to 28.3)
Joint pain: Mild15.0 (7.1 to 26.6)12.8 (4.3 to 27.4)11.8 (5.6 to 21.3)12.5 (5.2 to 24.1)
Joint pain: Moderate3.3 (0.4 to 11.5)10.3 (2.9 to 24.2)9.2 (3.8 to 18.1)3.6 (0.4 to 12.3)
Joint pain: Severe0.0 (0.0 to 6.0)2.6 (0.1 to 13.5)0.0 (0.0 to 4.7)0.0 (0.0 to 6.4)
PrimaryStage2: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Booster Vaccination: Group 1 Through Group 4
Time frame:
7 days after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Booster Vaccination: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Booster Vaccination: Group 1 Through Group 416.7 (8.3 to 28.5)20.5 (9.3 to 36.5)13.2 (6.5 to 22.9)10.7 (4.0 to 21.9)
PrimaryStage2: Percentage of Participants With at Least 1 SAE During Booster Vaccination Phase: Group 1 Through Group 4

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. SAE of "pregnancy" for one participant during the booster vaccination phase was recorded erroneously and hence it was included in results of Group 4.

Time frame:
Booster vaccination phase: From booster vaccination through 1 month after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 SAE During Booster Vaccination Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 SAE During Booster Vaccination Phase: Group 1 Through Group 40.0 (0.0 to 5.4)0.0 (0.0 to 8.8)0.0 (0.0 to 4.7)1.8 (0.0 to 9.6)
PrimaryStage2: Percentage of Participants With at Least 1 SAE During the Booster Follow-up Phase: Group 1 Through Group 4

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
Booster follow-up phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 SAE During the Booster Follow-up Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 SAE During the Booster Follow-up Phase: Group 1 Through Group 40.0 (0.0 to 5.4)0.0 (0.0 to 9.3)2.6 (0.3 to 9.1)0.0 (0.0 to 6.4)
PrimaryStage2: Percentage of Participants With at Least 1 SAE Throughout Booster Phase: Group 1 Through Group 4

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. SAE of "pregnancy" for one participant during the booster vaccination phase was recorded erroneously and hence it was reported in result of outcome measure 37 for Group 4. Subsequently correction was made by the trial site and not included in subsequent phase/results. Hence, that 1 participant is not included in results of Group 4 here.

Time frame:
Throughout Booster phase: From booster vaccination through 6 months after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 SAE Throughout Booster Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 SAE Throughout Booster Phase: Group 1 Through Group 40.0 (0.0 to 5.4)0.0 (0.0 to 8.8)2.6 (0.3 to 9.1)0.0 (0.0 to 6.4)
PrimaryStage2: Percentage of Participants With at Least 1 Medically Attended AE During Booster Vaccination Phase: Group 1 Through Group 4

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Booster vaccination phase: From booster vaccination through 1 month after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 Medically Attended AE During Booster Vaccination Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 Medically Attended AE During Booster Vaccination Phase: Group 1 Through Group 49.0 (3.4 to 18.5)5.0 (0.6 to 16.9)2.6 (0.3 to 9.1)7.1 (2.0 to 17.3)
PrimaryStage2: Percentage of Participants With at Least 1 Medically Attended AE During the Booster Follow-up Phase: Group 1 Through Group 4

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Booster Follow-up Phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 Medically Attended AE During the Booster Follow-up Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 Medically Attended AE During the Booster Follow-up Phase: Group 1 Through Group 43.0 (0.4 to 10.4)13.2 (4.4 to 28.1)6.5 (2.1 to 14.5)7.1 (2.0 to 17.3)
PrimaryStage2: Percentage of Participants With at Least 1 Medically Attended AE Throughout Booster Phase: Group 1 Through Group 4

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Throughout Booster Phase: From booster vaccination through 6 months after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 Medically Attended AE Throughout Booster Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 Medically Attended AE Throughout Booster Phase: Group 1 Through Group 410.4 (4.3 to 20.3)15.0 (5.7 to 29.8)7.8 (2.9 to 16.2)14.3 (6.4 to 26.2)
PrimaryStage2: Percentage of Participants With at Least 1 NDCMC During Booster Vaccination Phase: Group 1 Through Group 4

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 NDCMC During Booster Vaccination Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 NDCMC During Booster Vaccination Phase: Group 1 Through Group 40.0 (0.0 to 5.4)0.0 (0.0 to 8.8)0.0 (0.0 to 4.7)0.0 (0.0 to 6.4)
PrimaryStage2: Percentage of Participants With at Least 1 NDCMC During the Booster Follow-up Phase: Group 1 Through Group 4

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Booster Follow-up Phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 NDCMC During the Booster Follow-up Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 NDCMC During the Booster Follow-up Phase: Group 1 Through Group 40.0 (0.0 to 5.4)0.0 (0.0 to 9.3)2.6 (0.3 to 9.1)0.0 (0.0 to 6.4)
PrimaryStage2: Percentage of Participants With at Least 1 NDCMC Throughout Booster Phase: Group 1 Through Group 4

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Throughout Booster Phase: From booster vaccination through 6 months after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 NDCMC Throughout Booster Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 NDCMC Throughout Booster Phase: Group 1 Through Group 40.0 (0.0 to 5.4)0.0 (0.0 to 8.8)2.6 (0.3 to 9.1)0.0 (0.0 to 6.4)
PrimaryStage2: Percentage of Participants With at Least 1 AE During Booster Vaccination Phase: Group 1 Through Group 4

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 AE During Booster Vaccination Phase: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 AE During Booster Vaccination Phase: Group 1 Through Group 413.4 (6.3 to 24.0)10.0 (2.8 to 23.7)10.4 (4.6 to 19.4)17.9 (8.9 to 30.4)
PrimaryStage2: Percentage of Participants With at Least 1 Immediate AE After Booster Vaccination: Group 1 Through Group 4

Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

Time frame:
30 minutes after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With at Least 1 Immediate AE After Booster Vaccination: Group 1 Through Group 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Percentage of Participants With at Least 1 Immediate AE After Booster Vaccination: Group 1 Through Group 40.0 (0.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
PrimaryStage2: Number of Participants Who Missed School/Work Due to AE After Booster Vaccination: Group 1 Through Group 4
Time frame:
Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination
Reported as:
Count of participants · Participants
Stage2: Number of Participants Who Missed School/Work Due to AE After Booster Vaccination: Group 1 Through Group 4
ParticipantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Stage2: Number of Participants Who Missed School/Work Due to AE After Booster Vaccination: Group 1 Through Group 43032
SecondaryStage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>= LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).

Time frame:
1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22) 1 month after Vaccination 291.0 (88.8 to 92.8)
PMB2001 (A56) 1 month after Vaccination 299.4 (98.6 to 99.8)
PMB2948 (B24) 1 month after Vaccination 279.3 (76.4 to 82.0)
PMB2707 (B44) 1 month after Vaccination 294.5 (92.7 to 95.9)
SecondaryStage1: Percentage of Participants With hSBA Titer Level >= 1:4, >= 1:8, >= 1:16, >= 1:32, >= 1:64, >= 1:128 for All 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>= 1:4, \>= 1:8, \>= 1:16, \>= 1:32, \>= 1:64, \>= 1:128 for all 4 primary MenB test strains was reported in this outcome measure. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).

Time frame:
1 month after Vaccination 2 (Vacc 2)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA Titer Level >= 1:4, >= 1:8, >= 1:16, >= 1:32, >= 1:64, >= 1:128 for All 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22) 1 Month after Vacc 2 >=1:491.7 (89.6 to 93.4)
PMB80 (A22) 1 Month after Vacc 2 >=1:891.5 (89.5 to 93.3)
PMB80 (A22) 1 Month after Vacc 2 >=1:1691.0 (88.8 to 92.8)
PMB80 (A22) 1 Month after Vacc 2 >=1:3280.2 (77.3 to 82.8)
PMB80 (A22) 1 Month after Vacc 2 >=1:6454.9 (51.5 to 58.3)
PMB80 (A22) 1 Month after Vacc 2 >=1:12827.3 (24.4 to 30.5)
PMB2001 (A56) 1 Month after Vacc 2 >=1:499.5 (98.8 to 99.9)
PMB2001 (A56) 1 Month after Vacc 2 >=1:899.4 (98.6 to 99.8)
PMB2001 (A56) 1 Month after Vacc 2 >=1:1699.1 (98.2 to 99.6)
PMB2001 (A56) 1 Month after Vacc 2 >=1:3297.0 (95.6 to 98.0)
PMB2001 (A56) 1 Month after Vacc 2 >=1:6487.7 (85.3 to 89.8)
PMB2001 (A56) 1 Month after Vacc 2 >=1:12869.2 (66.0 to 72.3)
PMB2948 (B24) 1 Month after Vacc 2 >=1:481.2 (78.4 to 83.8)
PMB2948 (B24) 1 Month after Vacc 2 >=1:879.3 (76.4 to 82.0)
PMB2948 (B24) 1 Month after Vacc 2 >=1:1674.0 (70.9 to 76.9)
PMB2948 (B24) 1 Month after Vacc 2 >=1:3247.9 (44.4 to 51.3)
PMB2948 (B24) 1 Month after Vacc 2 >=1:6424.9 (22.1 to 28.0)
PMB2948 (B24) 1 Month after Vacc 2 >=1:1289.6 (7.7 to 11.8)
PMB2707 (B44) 1 Month after Vacc 2 >=1:496.2 (94.7 to 97.4)
PMB2707 (B44) 1 Month after Vacc 2 >=1:894.5 (92.7 to 95.9)
PMB2707 (B44) 1 Month after Vacc 2 >=1:1689.0 (86.7 to 91.0)
PMB2707 (B44) 1 Month after Vacc 2 >=1:3268.6 (65.3 to 71.7)
PMB2707 (B44) 1 Month after Vacc 2 >=1:6441.0 (37.7 to 44.4)
PMB2707 (B44) 1 Month after Vacc 2 >=1:12819.2 (16.6 to 22.0)
SecondaryStage1: hSBA Geometric Mean Titers (GMTs) for All 4 Primary MenB Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)

GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5 \* LLOQ for analysis. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).

Time frame:
1 month after Vaccination 2 (Vacc 2)
Reported as:
Geometric mean · Titers
Stage1: hSBA Geometric Mean Titers (GMTs) for All 4 Primary MenB Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)
TitersGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22) 1 month after Vacc 249.3 (46.2 to 52.6)
PMB2001 (A56) 1 month after Vacc 2139.5 (130.6 to 149.1)
PMB2948 (B24) 1 month after Vacc 221.2 (19.6 to 22.9)
PMB2707 (B44) 1 month after Vacc 237.8 (35.1 to 40.8)
SecondaryStage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer greater than or equal to LLOQ for 10 Secondary MenB test strains combined (LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16) was reported in this outcome measure.

Time frame:
1 month after Vaccination 2 (Vacc 2)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB3175 (A29) 1 month after Vacc 295.2 (90.7 to 97.9)
PMB3010 (A06) 1 month after Vacc 289.3 (83.4 to 93.6)
PMB824 (A12) 1 month after Vacc 283.4 (76.7 to 88.9)
PMB3040 (A07) 1 month after Vacc 296.8 (92.7 to 99.0)
PMB1672 (A15) 1 month after Vacc 289.1 (83.3 to 93.4)
PMB1989 (A19) 1 month after Vacc 290.4 (84.9 to 94.4)
PMB648 (B16) 1 month after Vacc 277.4 (70.3 to 83.6)
PMB866 (B09) 1 month after Vacc 271.1 (63.6 to 77.8)
PMB1256 (B03) 1 month after Vacc 274.4 (67.0 to 80.9)
PMB431 (B15) 1 month after Vacc 285.0 (78.7 to 90.1)
SecondaryStage1: Percentage of Participants With hSBA Titer Level >= 1:4, >= 1:8, >= 1:16, >= 1:32, >= 1:64, >= 1:128 for Each of the 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>= 1:4, \>= 1:8, \>= 1:16, \>= 1:32, \>= 1:64, \>= 1:128 for each of the 10 secondary MenB test strains was reported in this outcome measure. 10 secondary MenB test strains were PMB3175 (A29), PMB3010 (A06), PMB824 (A12), PMB3040 (A07), PMB1672 (A15), PMB1989 (A19), PMB648 (B16), PMB866 (B09), PMB1256 (B03) and PMB431 (B15).

Time frame:
1 month after Vaccination 2 (Vacc 2)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA Titer Level >= 1:4, >= 1:8, >= 1:16, >= 1:32, >= 1:64, >= 1:128 for Each of the 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participantsGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB3175 (A29) 1 Month after Vacc 2 >=1:495.8 (91.5 to 98.3)
PMB3175 (A29) 1 Month after Vacc 2 >=1:895.2 (90.7 to 97.9)
PMB3175 (A29) 1 Month after Vacc 2 >=1:1692.2 (87.0 to 95.8)
PMB3175 (A29) 1 Month after Vacc 2 >=1:3271.7 (64.2 to 78.4)
PMB3175 (A29) 1 Month after Vacc 2 >=1:6438.0 (30.5 to 45.8)
PMB3175 (A29) 1 Month after Vacc 2 >=1:12813.9 (9.0 to 20.1)
PMB3010 (A06) 1 Month after Vacc 2 >=1:489.9 (84.2 to 94.1)
PMB3010 (A06) 1 Month after Vacc 2 >=1:889.3 (83.4 to 93.6)
PMB3010 (A06) 1 Month after Vacc 2 >=1:1689.3 (83.4 to 93.6)
PMB3010 (A06) 1 Month after Vacc 2 >=1:3279.9 (72.8 to 85.8)
PMB3010 (A06) 1 Month after Vacc 2 >=1:6454.7 (46.6 to 62.6)
PMB3010 (A06) 1 Month after Vacc 2 >=1:12822.0 (15.8 to 29.3)
PMB824 (A12) 1 Month after Vacc 2 >=1:489.2 (83.2 to 93.6)
PMB824 (A12) 1 Month after Vacc 2 >=1:887.9 (81.7 to 92.6)
PMB824 (A12) 1 Month after Vacc 2 >=1:1683.4 (76.7 to 88.9)
PMB824 (A12) 1 Month after Vacc 2 >=1:3252.9 (44.8 to 60.9)
PMB824 (A12) 1 Month after Vacc 2 >=1:6418.5 (12.7 to 25.4)
PMB824 (A12) 1 Month after Vacc 2 >=1:1281.3 (0.2 to 4.5)
PMB3040 (A07) 1 Month after Vacc 2 >=1:496.8 (92.7 to 99.0)
PMB3040 (A07) 1 Month after Vacc 2 >=1:896.8 (92.7 to 99.0)
PMB3040 (A07) 1 Month after Vacc 2 >=1:1696.8 (92.7 to 99.0)
PMB3040 (A07) 1 Month after Vacc 2 >=1:3294.3 (89.4 to 97.3)
PMB3040 (A07) 1 Month after Vacc 2 >=1:6468.8 (60.9 to 75.9)
PMB3040 (A07) 1 Month after Vacc 2 >=1:12831.2 (24.1 to 39.1)
PMB1672 (A15) 1 Month after Vacc 2 >=1:489.1 (83.3 to 93.4)
PMB1672 (A15) 1 Month after Vacc 2 >=1:889.1 (83.3 to 93.4)
PMB1672 (A15) 1 Month after Vacc 2 >=1:1687.3 (81.2 to 91.9)
PMB1672 (A15) (n=165) 1 Month after Vacc 2 >=1:3269.7 (62.1 to 76.6)
PMB1672 (A15) 1 Month after Vacc 2 >=1:6430.3 (23.4 to 37.9)
PMB1672 (A15) 1 Month after Vacc 2 >=1:1285.5 (2.5 to 10.1)
PMB1989 (A19) 1 Month after Vacc 2 >=1:492.2 (87.1 to 95.8)
PMB1989 (A19) 1 Month after Vacc 2 >=1:892.2 (87.1 to 95.8)
PMB1989 (A19) 1 Month after Vacc 2 >=1:1690.4 (84.9 to 94.4)
PMB1989 (A19) 1 Month after Vacc 2 >=1:3284.4 (78.0 to 89.6)
PMB1989 (A19) 1 Month after Vacc 2 >=1:6461.1 (53.2 to 68.5)
PMB1989 (A19) 1 Month after Vacc 2 >=1:12828.7 (22.0 to 36.2)
PMB648 (B16) 1 Month after Vacc 2 >=1:479.3 (72.3 to 85.2)
PMB648 (B16) 1 Month after Vacc 2 >=1:877.4 (70.3 to 83.6)
PMB648 (B16) 1 Month after Vacc 2 >=1:1673.8 (66.4 to 80.3)
PMB648 (B16) 1 Month after Vacc 2 >=1:3251.2 (43.3 to 59.1)
PMB648 (B16) 1 Month after Vacc 2 >=1:6428.7 (21.9 to 36.2)
PMB648 (B16) 1 Month after Vacc 2 >=1:1286.1 (3.0 to 10.9)
PMB866 (B09) 1 Month after Vacc 2 >=1:474.7 (67.4 to 81.1)
PMB866 (B09) 1 Month after Vacc 2 >=1:871.1 (63.6 to 77.8)
PMB866 (B09) 1 Month after Vacc 2 >=1:1663.3 (55.4 to 70.6)
PMB866 (B09) 1 Month after Vacc 2 >=1:3234.3 (27.2 to 42.1)
PMB866 (B09) 1 Month after Vacc 2 >=1:648.4 (4.7 to 13.7)
PMB866 (B09) 1 Month after Vacc 2 >=1:1282.4 (0.7 to 6.1)
PMB1256 (B03) 1 Month after Vacc 2 >=1:477.4 (70.3 to 83.6)
PMB1256 (B03) 1 Month after Vacc 2 >=1:874.4 (67.0 to 80.9)
PMB1256 (B03) 1 Month after Vacc 2 >=1:1664.0 (56.2 to 71.4)
PMB1256 (B03) 1 Month after Vacc 2 >=1:3242.1 (34.4 to 50.0)
PMB1256 (B03) 1 Month after Vacc 2 >=1:6423.2 (16.9 to 30.4)
PMB1256 (B03) 1 Month after Vacc 2 >=1:1287.3 (3.8 to 12.4)
PMB431 (B15) 1 Month after Vacc 2 >=1:487.4 (81.4 to 92.0)
PMB431 (B15) 1 Month after Vacc 2 >=1:885.0 (78.7 to 90.1)
PMB431 (B15) 1 Month after Vacc 2 >=1:1672.5 (65.0 to 79.1)
PMB431 (B15) 1 Month after Vacc 2 >=1:3236.5 (29.2 to 44.3)
PMB431 (B15) 1 Month after Vacc 2 >=1:6415.0 (9.9 to 21.3)
PMB431 (B15) 1 Month after Vacc 2 >=1:1282.4 (0.7 to 6.0)
SecondaryStage1: hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)

GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.

Time frame:
1 month after Vaccination 2 (Vacc 2)
Reported as:
Geometric mean · Titers
Stage1: hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
TitersGroups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB3175 (A29) 1 month after Vacc 235.7 (30.9 to 41.2)
PMB3010 (A06) 1 month after Vacc 246.0 (39.7 to 53.1)
PMB824 (A12) 1 month after Vacc 223.7 (21.2 to 26.5)
PMB3040 (A07) 1 month after Vacc 260.7 (53.6 to 68.8)
PMB1672 (A15) 1 month after Vacc 228.4 (24.7 to 32.7)
PMB1989 (A19) 1 month after Vacc 253.5 (46.3 to 61.9)
PMB648 (B16) 1 month after Vacc 220.8 (17.5 to 24.6)
PMB866 (B09) 1 month after Vacc 213.9 (12.0 to 16.2)
PMB1256 (B03) 1 month after Vacc 217.7 (14.8 to 21.3)
PMB431 (B15) 1 month after Vacc 217.3 (15.1 to 19.8)
SecondaryStage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=LLOQ for ACWY Test Strains 1 Month After the Vaccination 1: Groups 1, 2, 3 and 4

Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.

Time frame:
1 month after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=LLOQ for ACWY Test Strains 1 Month After the Vaccination 1: Groups 1, 2, 3 and 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
MenA99.2 (97.3 to 99.9)98.4 (96.9 to 99.3)100.0 (98.3 to 100.0)99.3 (97.9 to 99.8)
MenC92.4 (88.5 to 95.3)88.6 (85.5 to 91.2)100.0 (98.6 to 100.0)99.4 (98.3 to 99.9)
MenW98.5 (96.2 to 99.6)95.5 (93.3 to 97.1)99.5 (97.5 to 100.0)99.5 (98.3 to 99.9)
MenY99.6 (97.9 to 100.0)96.9 (95.0 to 98.2)99.5 (97.5 to 100.0)99.8 (98.7 to 100.0)
SecondaryStage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for ACWY Test Strains 1 Month After the Vaccination 1: Groups 1, 2, 3 and 4

Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.

Time frame:
1 month after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for ACWY Test Strains 1 Month After the Vaccination 1: Groups 1, 2, 3 and 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
MenA >=1:499.6 (97.9 to 100.0)98.4 (96.9 to 99.3)100.0 (98.3 to 100.0)99.3 (97.9 to 99.8)
MenA >=1:899.2 (97.3 to 99.9)98.4 (96.9 to 99.3)100.0 (98.3 to 100.0)99.3 (97.9 to 99.8)
MenA >=1:1698.5 (96.2 to 99.6)98.0 (96.4 to 99.1)100.0 (98.3 to 100.0)99.3 (97.9 to 99.8)
MenA >=1:3297.7 (95.1 to 99.2)93.9 (91.5 to 95.8)99.5 (97.5 to 100.0)99.0 (97.5 to 99.7)
MenA >=1:6490.9 (86.8 to 94.1)86.3 (83.0 to 89.1)99.1 (96.7 to 99.9)98.3 (96.5 to 99.3)
MenA >= 1:12875.0 (69.3 to 80.1)71.2 (67.0 to 75.1)95.4 (91.7 to 97.8)96.4 (94.1 to 97.9)
MenC >=1:495.4 (92.1 to 97.6)93.3 (90.8 to 95.3)100.0 (98.6 to 100.0)99.4 (98.3 to 99.9)
MenC >=1:892.4 (88.5 to 95.3)88.6 (85.5 to 91.2)100.0 (98.6 to 100.0)99.4 (98.3 to 99.9)
MenC >=1:1688.2 (83.6 to 91.8)80.9 (77.3 to 84.3)100.0 (98.6 to 100.0)99.2 (98.0 to 99.8)
MenC >=1:3276.3 (70.7 to 81.3)67.8 (63.5 to 71.8)98.9 (96.7 to 99.8)98.2 (96.7 to 99.2)
MenC >=1:6461.8 (55.7 to 67.7)55.0 (50.6 to 59.4)97.3 (94.6 to 98.9)97.2 (95.4 to 98.5)
MenC >=1:12850.8 (44.5 to 57.0)45.6 (41.2 to 50.0)95.5 (92.2 to 97.6)94.1 (91.6 to 96.0)
MenW >=1:499.6 (97.9 to 100.0)97.7 (95.9 to 98.8)100.0 (98.3 to 100.0)99.5 (98.3 to 99.9)
MenW >=1:898.5 (96.2 to 99.6)95.5 (93.3 to 97.1)99.5 (97.5 to 100.0)99.5 (98.3 to 99.9)
MenW >=1:1696.2 (93.1 to 98.2)89.3 (86.2 to 91.8)99.5 (97.5 to 100.0)99.3 (97.9 to 99.9)
MenW >=1:3282.2 (77.0 to 86.6)75.0 (71.0 to 78.7)99.5 (97.5 to 100.0)98.1 (96.2 to 99.2)
MenW >=1:6465.9 (59.8 to 71.6)56.1 (51.6 to 60.4)99.1 (96.7 to 99.9)96.6 (94.4 to 98.1)
MenW >=1:12843.9 (37.9 to 50.2)38.1 (33.9 to 42.4)98.6 (96.0 to 99.7)94.0 (91.2 to 96.1)
MenY >=1:4100.0 (98.6 to 100.0)99.2 (98.0 to 99.8)99.5 (97.5 to 100.0)100.0 (99.1 to 100.0)
MenY >=1:899.6 (97.9 to 100.0)96.9 (95.0 to 98.2)99.5 (97.5 to 100.0)99.8 (98.7 to 100.0)
MenY >=1:1698.9 (96.7 to 99.8)92.9 (90.4 to 95.0)99.5 (97.5 to 100.0)99.3 (97.9 to 99.8)
MenY >=1:3292.4 (88.5 to 95.3)82.4 (78.8 to 85.6)99.1 (96.7 to 99.9)99.0 (97.5 to 99.7)
MenY >=1:6478.3 (72.9 to 83.2)66.9 (62.6 to 70.9)99.1 (96.7 to 99.9)97.1 (95.0 to 98.5)
MenY >=1:12862.0 (55.8 to 67.9)48.6 (44.2 to 53.1)98.6 (96.0 to 99.7)94.9 (92.3 to 96.8)
SecondaryStage1: hSBA Geometric Mean Titers (GMTs) for ACWY Test Strains 1 Month After Vaccination 1: Groups 1, 2, 3 and 4

GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.

Time frame:
1 month after Vaccination 1
Reported as:
Geometric mean · Titers
Stage1: hSBA Geometric Mean Titers (GMTs) for ACWY Test Strains 1 Month After Vaccination 1: Groups 1, 2, 3 and 4
TitersGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
MenA215.8 (184.6 to 252.4)203.2 (178.7 to 231.0)568.6 (492.9 to 656.0)916.1 (809.1 to 1037.3)
MenC111.5 (87.2 to 142.6)81.4 (68.1 to 97.4)814.9 (689.4 to 963.2)827.0 (722.5 to 946.6)
MenW98.4 (80.7 to 120.0)71.2 (61.5 to 82.4)1214.9 (1032.0 to 1430.1)1176.7 (1017.9 to 1360.2)
MenY141.9 (118.8 to 169.4)96.6 (83.9 to 111.2)1174.0 (990.3 to 1391.9)1000.2 (872.1 to 1147.1)
SecondaryStage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or LLOQ, Whichever is Higher) for ACWY Test Strains 1 Month After the Vaccination 1 in Groups 2 and 4, and 1 Month After Vaccination 2 in Groups 1 and 3

Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>= LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.

Time frame:
For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or LLOQ, Whichever is Higher) for ACWY Test Strains 1 Month After the Vaccination 1 in Groups 2 and 4, and 1 Month After Vaccination 2 in Groups 1 and 3
Percentage of participantsGroup 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Group 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
MenA98.4 (96.9 to 99.3)99.3 (97.9 to 99.8)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenC88.6 (85.5 to 91.2)99.4 (98.3 to 99.9)100.0 (98.4 to 100.0)99.6 (97.7 to 100.0)
MenW95.5 (93.3 to 97.1)99.5 (98.3 to 99.9)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenY96.9 (95.0 to 98.2)99.8 (98.7 to 100.0)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
SecondaryStage1: Percentage of Participants With MenA, MenC, MenW, and MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and, >=1:128 for ACWY Test Strains 1 Month After Vaccination 1 in Groups 2 and 4, and 1 Month After Vaccination 2 in Groups 1 and 3

Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.

Time frame:
For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With MenA, MenC, MenW, and MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and, >=1:128 for ACWY Test Strains 1 Month After Vaccination 1 in Groups 2 and 4, and 1 Month After Vaccination 2 in Groups 1 and 3
Percentage of participantsGroup 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Group 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
MenA >=1:498.4 (96.9 to 99.3)99.3 (97.9 to 99.8)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenA >=1:898.4 (96.9 to 99.3)99.3 (97.9 to 99.8)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenA >=1:1698.0 (96.4 to 99.1)99.3 (97.9 to 99.8)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenA >=1:3293.9 (91.5 to 95.8)99.0 (97.5 to 99.7)97.8 (95.0 to 99.3)99.5 (97.1 to 100.0)
MenA >=1:6486.3 (83.0 to 89.1)98.3 (96.5 to 99.3)92.2 (88.0 to 95.3)97.4 (94.0 to 99.1)
MenA >=1:12871.2 (67.0 to 75.1)96.4 (94.1 to 97.9)69.4 (63.0 to 75.3)92.7 (88.0 to 95.9)
MenC >=1:493.3 (90.8 to 95.3)99.4 (98.3 to 99.9)100.0 (98.4 to 100.0)99.6 (97.7 to 100.0)
MenC >=1:888.6 (85.5 to 91.2)99.4 (98.3 to 99.9)100.0 (98.4 to 100.0)99.6 (97.7 to 100.0)
MenC >=1:1680.9 (77.3 to 84.3)99.2 (98.0 to 99.8)99.6 (97.6 to 100.0)99.6 (97.7 to 100.0)
MenC >=1:3267.8 (63.5 to 71.8)98.2 (96.7 to 99.2)97.4 (94.4 to 99.0)99.6 (97.7 to 100.0)
MenC >=1:6455.0 (50.6 to 59.4)97.2 (95.4 to 98.5)90.9 (86.4 to 94.3)98.3 (95.7 to 99.5)
MenC >=1:12845.6 (41.2 to 50.0)94.1 (91.6 to 96.0)78.8 (72.9 to 83.9)92.8 (88.8 to 95.8)
MenW >=1:497.7 (95.9 to 98.8)99.5 (98.3 to 99.9)100.0 (98.4 to 100.0)100.0 (98.1 to 100.0)
MenW >=1:895.5 (93.3 to 97.1)99.5 (98.3 to 99.9)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenW >=1:1689.3 (86.2 to 91.8)99.3 (97.9 to 99.9)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenW >=1:3275.0 (71.0 to 78.7)98.1 (96.2 to 99.2)99.6 (97.6 to 100.0)99.5 (97.1 to 100.0)
MenW >=1:6456.1 (51.6 to 60.4)96.6 (94.4 to 98.1)97.0 (93.9 to 98.8)99.0 (96.3 to 99.9)
MenW >=1:12838.1 (33.9 to 42.4)94.0 (91.2 to 96.1)89.7 (85.1 to 93.3)97.9 (94.7 to 99.4)
MenY >=1:499.2 (98.0 to 99.8)100.0 (99.1 to 100.0)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenY >=1:896.9 (95.0 to 98.2)99.8 (98.7 to 100.0)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenY >=1:1692.9 (90.4 to 95.0)99.3 (97.9 to 99.8)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenY >=1:3282.4 (78.8 to 85.6)99.0 (97.5 to 99.7)100.0 (98.4 to 100.0)99.5 (97.1 to 100.0)
MenY >=1:6466.9 (62.6 to 70.9)97.1 (95.0 to 98.5)97.4 (94.5 to 99.0)99.5 (97.1 to 100.0)
MenY >=1:12848.6 (44.2 to 53.1)94.9 (92.3 to 96.8)89.7 (85.1 to 93.3)95.3 (91.2 to 97.8)
SecondaryStage1: hSBA GMTs for ACWY Test Strains 1 Month After Vaccination 1 in Groups 2 and 4 and 1 Month After Vaccination 2 in Groups 1 and 3

GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.

Time frame:
For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2
Reported as:
Geometric mean · Titers
Stage1: hSBA GMTs for ACWY Test Strains 1 Month After Vaccination 1 in Groups 2 and 4 and 1 Month After Vaccination 2 in Groups 1 and 3
TitersGroup 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Group 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
MenA203.2 (178.7 to 231.0)916.1 (809.1 to 1037.3)151.3 (134.1 to 170.7)337.3 (291.7 to 390.0)
MenC81.4 (68.1 to 97.4)827.0 (722.5 to 946.6)229.1 (194.7 to 269.5)498.7 (429.1 to 579.6)
MenW71.2 (61.5 to 82.4)1176.7 (1017.9 to 1360.2)274.1 (242.7 to 309.7)570.9 (484.3 to 673.0)
MenY96.6 (83.9 to 111.2)1000.2 (872.1 to 1147.1)301.5 (266.6 to 341.0)558.6 (470.0 to 663.9)
SecondaryStage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

Time frame:
1 month after Vaccination 2 (Vacc 2)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participantsGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22) 1 month after Vacc 291.0 (87.9 to 93.5)91.0 (88.8 to 92.8)
PMB2001 (A56) 1 month after Vacc 298.6 (97.0 to 99.5)99.4 (98.6 to 99.8)
PMB2948 (B24) 1 month after Vacc 284.3 (80.5 to 87.6)79.3 (76.4 to 82.0)
PMB2707 (B44) 1 month after Vacc 295.4 (93.0 to 97.2)94.5 (92.7 to 95.9)
SecondaryStage1: Percentage of Participants With >=4 Fold Rise in hSBA for 4 Primary MenB Strains and Composite Response (hSBA >=LLOQ for All 4 Primary MenB Strains Combined) From Baseline-1 Month After Vaccination 2 (Group 1 and 3 Combined;Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer greater than or equal to LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

Time frame:
Baseline to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With >=4 Fold Rise in hSBA for 4 Primary MenB Strains and Composite Response (hSBA >=LLOQ for All 4 Primary MenB Strains Combined) From Baseline-1 Month After Vaccination 2 (Group 1 and 3 Combined;Group 2 and 4 Combined)
Percentage of participantsGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22)75.8 (71.5 to 79.8)73.8 (70.6 to 76.7)
PMB2001 (A56)94.7 (92.1 to 96.7)95.0 (93.3 to 96.4)
PMB2948 (B24)76.1 (71.7 to 80.1)67.4 (64.1 to 70.6)
PMB2707 (B44)91.7 (88.6 to 94.1)86.4 (83.9 to 88.6)
Composite hSBA response79.9 (75.7 to 83.6)74.3 (71.2 to 77.3)
SecondaryStage1: Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for Each of the 4 Primary MenB Test Strains From 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 for all 4 primary MenB test strains was reported in this outcome measure.

Time frame:
1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for Each of the 4 Primary MenB Test Strains From 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participantsGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22) >=1:491.9 (88.9 to 94.3)91.7 (89.6 to 93.4)
PMB80 (A22) >=1:891.7 (88.7 to 94.1)91.5 (89.5 to 93.3)
PMB80 (A22) >=1:1691.0 (87.9 to 93.5)91.0 (88.8 to 92.8)
PMB80 (A22) >=1:3282.4 (78.5 to 85.9)80.2 (77.3 to 82.8)
PMB80 (A22) >=1:6458.0 (53.2 to 62.7)54.9 (51.5 to 58.3)
PMB80 (A22) >=1:12827.9 (23.8 to 32.4)27.3 (24.4 to 30.5)
PMB2001 (A56) >=1:498.9 (97.3 to 99.6)99.5 (98.8 to 99.9)
PMB2001 (A56) >=1:898.6 (97.0 to 99.5)99.4 (98.6 to 99.8)
PMB2001 (A56) >=1:1698.6 (97.0 to 99.5)99.1 (98.2 to 99.6)
PMB2001 (A56) >=1:3296.8 (94.7 to 98.2)97.0 (95.6 to 98.0)
PMB2001 (A56) >=1:6490.1 (86.9 to 92.8)87.7 (85.3 to 89.8)
PMB2001 (A56) >=1:12874.0 (69.6 to 78.1)69.2 (66.0 to 72.3)
PMB2948 (B24) >=1:486.9 (83.3 to 89.9)81.2 (78.4 to 83.8)
PMB2948 (B24) >=1:884.3 (80.5 to 87.6)79.3 (76.4 to 82.0)
PMB2948 (B24) >=1:1680.8 (76.7 to 84.4)74.0 (70.9 to 76.9)
PMB2948 (B24) >=1:3258.5 (53.6 to 63.2)47.9 (44.4 to 51.3)
PMB2948 (B24) >=1:6431.0 (26.6 to 35.6)24.9 (22.1 to 28.0)
PMB2948 (B24) >=1:12813.4 (10.3 to 17.0)9.6 (7.7 to 11.8)
PMB2707 (B44) >=1:497.2 (95.2 to 98.6)96.2 (94.7 to 97.4)
PMB2707 (B44) >=1:895.4 (93.0 to 97.2)94.5 (92.7 to 95.9)
PMB2707 (B44) >=1:1692.4 (89.5 to 94.7)89.0 (86.7 to 91.0)
PMB2707 (B44) >=1:3272.9 (68.5 to 77.1)68.6 (65.3 to 71.7)
PMB2707 (B44) >=1:6448.9 (44.1 to 53.7)41.0 (37.7 to 44.4)
PMB2707 (B44) >=1:12822.0 (18.2 to 26.2)19.2 (16.6 to 22.0)
SecondaryStage1: hSBA GMTs for Each of the 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ =1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.

Time frame:
1 month after Vaccination 2
Reported as:
Geometric mean · Titers
Stage1: hSBA GMTs for Each of the 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
TitersGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22)51.0 (46.7 to 55.7)49.3 (46.2 to 52.6)
PMB2001 (A56)152.3 (138.5 to 167.5)139.5 (130.6 to 149.1)
PMB2948 (B24)26.6 (23.9 to 29.7)21.2 (19.6 to 22.9)
PMB2707 (B44)43.3 (39.1 to 47.9)37.8 (35.1 to 40.8)
SecondaryStage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW and hSBA-MenY Titers >=1:8 (or LLOQ) for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4

Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.

Time frame:
Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW and hSBA-MenY Titers >=1:8 (or LLOQ) for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
MenA Before Vacc 115.9 (11.8 to 20.8)22.9 (19.4 to 26.7)53.9 (47.0 to 60.6)52.6 (47.7 to 57.5)
MenA Before Vacc 291.6 (87.3 to 94.8)86.2 (82.7 to 89.2)99.0 (96.4 to 99.9)98.4 (96.6 to 99.4)
MenC Before Vacc 138.6 (32.7 to 44.7)39.0 (34.8 to 43.3)59.5 (53.3 to 65.4)61.1 (56.7 to 65.3)
MenC Before Vacc 292.9 (88.9 to 95.8)76.5 (72.4 to 80.3)98.4 (95.8 to 99.5)98.3 (96.7 to 99.3)
MenW Before Vacc 132.1 (26.5 to 38.0)34.5 (30.5 to 38.8)61.9 (55.1 to 68.4)60.8 (55.9 to 65.5)
MenW Before Vacc 299.2 (97.0 to 99.9)91.0 (88.0 to 93.4)100.0 (98.2 to 100.0)99.0 (97.4 to 99.7)
MenY Before Vacc 154.0 (47.8 to 60.1)58.1 (53.8 to 62.4)79.9 (74.0 to 85.0)77.9 (73.6 to 81.8)
MenY Before Vacc 2100.0 (98.5 to 100.0)97.2 (95.2 to 98.5)100.0 (98.2 to 100.0)99.5 (98.1 to 99.9)
SecondaryStage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4

Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>= :8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.

Time frame:
Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
MenA Before Vacc 1 >=1:426.3 (21.1 to 32.0)33.3 (29.3 to 37.5)64.4 (57.7 to 70.7)65.8 (61.0 to 70.3)
MenA Before Vacc 1 >=1:815.9 (11.8 to 20.8)22.9 (19.4 to 26.7)53.9 (47.0 to 60.6)52.6 (47.7 to 57.5)
MenA Before Vacc 1 >=1:1614.4 (10.5 to 19.2)18.0 (14.8 to 21.5)40.2 (33.6 to 47.0)41.6 (36.9 to 46.5)
MenA Before Vacc 1 >=1:328.5 (5.5 to 12.5)10.6 (8.1 to 13.6)24.2 (18.7 to 30.4)22.0 (18.1 to 26.3)
MenA Before Vacc 1 >=1:645.2 (2.9 to 8.5)5.5 (3.7 to 7.8)12.8 (8.7 to 17.9)15.1 (11.8 to 18.9)
MenA Before Vacc 1 >=1:1283.0 (1.3 to 5.8)4.0 (2.5 to 6.0)7.8 (4.6 to 12.1)6.2 (4.1 to 9.0)
MenA Before Vacc 2 >=1:493.3 (89.3 to 96.1)88.3 (85.1 to 91.1)99.0 (96.4 to 99.9)98.4 (96.6 to 99.4)
MenA Before Vacc 2 >=1:891.6 (87.3 to 94.8)86.2 (82.7 to 89.2)99.0 (96.4 to 99.9)98.4 (96.6 to 99.4)
MenA Before Vacc 2 >=1:1687.4 (82.5 to 91.3)81.9 (78.0 to 85.3)98.0 (95.0 to 99.5)98.4 (96.6 to 99.4)
MenA Before Vacc 2 >=1:3272.3 (66.1 to 77.9)66.3 (61.8 to 70.6)95.5 (91.6 to 97.9)96.1 (93.7 to 97.8)
MenA Before Vacc 2 >=1:6444.5 (38.1 to 51.1)50.5 (45.9 to 55.2)85.0 (79.3 to 89.6)88.8 (85.3 to 91.8)
MenA Before Vacc 2 >=1:12825.2 (19.8 to 31.2)33.5 (29.2 to 38.0)64.0 (56.9 to 70.6)75.3 (70.7 to 79.6)
MenC Before Vacc 1 >=1:463.7 (57.6 to 69.4)59.7 (55.4 to 63.9)76.1 (70.5 to 81.1)78.3 (74.4 to 81.8)
MenC Before Vacc 1 >=1:838.6 (32.7 to 44.7)39.0 (34.8 to 43.3)59.5 (53.3 to 65.4)61.1 (56.7 to 65.3)
MenC Before Vacc 1 >=1:1624.3 (19.3 to 29.9)24.5 (20.9 to 28.4)42.0 (36.0 to 48.3)44.4 (40.1 to 48.9)
MenC Before Vacc 1 >=1:3212.0 (8.3 to 16.5)12.5 (9.8 to 15.7)26.9 (21.6 to 32.7)29.7 (25.8 to 33.9)
MenC Before Vacc 1 >=1:645.2 (2.9 to 8.6)6.8 (4.8 to 9.3)15.9 (11.7 to 20.9)18.2 (14.9 to 21.8)
MenC Before Vacc 1 >=1:1284.5 (2.3 to 7.7)4.0 (2.5 to 6.0)6.8 (4.1 to 10.6)9.2 (6.8 to 12.0)
MenC Before Vacc 2 >=1:495.0 (91.4 to 97.4)85.9 (82.3 to 88.9)99.6 (97.7 to 100.0)99.4 (98.2 to 99.9)
MenC Before Vacc 2 >=1:892.9 (88.9 to 95.8)76.5 (72.4 to 80.3)98.4 (95.8 to 99.5)98.3 (96.7 to 99.3)
MenC Before Vacc 2 >=1:1684.9 (79.8 to 89.2)68.3 (63.8 to 72.5)98.4 (95.8 to 99.5)97.3 (95.4 to 98.5)
MenC Before Vacc 2 >=1:3268.2 (61.9 to 74.1)52.4 (47.7 to 57.0)95.9 (92.6 to 98.0)91.6 (88.7 to 93.9)
MenC Before Vacc 2 >=1:6453.1 (46.6 to 59.6)39.3 (34.9 to 44.0)92.6 (88.5 to 95.6)81.2 (77.4 to 84.6)
MenC Before Vacc 2 >=1:12836.8 (30.7 to 43.3)27.8 (23.8 to 32.2)78.2 (72.5 to 83.2)66.2 (61.8 to 70.5)
MenW Before Vacc 1 >=1:447.8 (41.6 to 53.9)50.5 (46.1 to 54.8)83.0 (77.4 to 87.8)76.3 (71.9 to 80.3)
MenW Before Vacc 1 >=1:832.1 (26.5 to 38.0)34.5 (30.5 to 38.8)61.9 (55.1 to 68.4)60.8 (55.9 to 65.5)
MenW Before Vacc 1 >=1:1623.9 (18.9 to 29.4)22.8 (19.3 to 26.6)37.6 (31.2 to 44.4)39.7 (35.0 to 44.6)
MenW Before Vacc 1 >=1:3210.8 (7.4 to 15.2)13.7 (10.8 to 16.9)20.2 (15.1 to 26.1)21.8 (17.9 to 26.0)
MenW Before Vacc 1 >=1:647.5 (4.6 to 11.3)6.3 (4.3 to 8.7)9.2 (5.7 to 13.8)11.2 (8.4 to 14.7)
MenW Before Vacc 1 >=1:1284.5 (2.3 to 7.7)1.5 (0.7 to 3.0)5.5 (2.9 to 9.4)6.2 (4.1 to 9.0)
MenW Before Vacc 2 >=1:499.2 (97.0 to 99.9)96.6 (94.5 to 98.0)100.0 (98.2 to 100.0)99.0 (97.4 to 99.7)
MenW Before Vacc 2 >=1:899.2 (97.0 to 99.9)91.0 (88.0 to 93.4)100.0 (98.2 to 100.0)99.0 (97.4 to 99.7)
MenW Before Vacc 2 >=1:1695.5 (92.0 to 97.7)82.7 (78.9 to 86.0)99.5 (97.2 to 100.0)97.7 (95.6 to 98.9)
MenW Before Vacc 2 >=1:3278.5 (72.8 to 83.5)64.2 (59.7 to 68.6)98.5 (95.7 to 99.7)95.8 (93.3 to 97.6)
MenW Before Vacc 2 >=1:6456.6 (50.1 to 62.9)41.1 (36.6 to 45.7)95.5 (91.6 to 97.9)89.1 (85.5 to 92.0)
MenW Before Vacc 2 >=1:12834.3 (28.3 to 40.6)24.2 (20.4 to 28.3)84.4 (78.6 to 89.2)79.0 (74.5 to 82.9)
MenY Before Vacc 1 >=1:467.2 (61.2 to 72.8)70.3 (66.2 to 74.1)87.7 (82.6 to 91.7)89.5 (86.2 to 92.3)
MenY Before Vacc 1 >=1:854.0 (47.8 to 60.1)58.1 (53.8 to 62.4)79.9 (74.0 to 85.0)77.9 (73.6 to 81.8)
MenY Before Vacc 1 >=1:1644.2 (38.1 to 50.4)46.6 (42.3 to 50.9)67.1 (60.5 to 73.3)65.8 (61.0 to 70.3)
MenY Before Vacc 1 >=1:3221.1 (16.4 to 26.5)26.7 (23.0 to 30.7)38.4 (31.9 to 45.1)40.9 (36.1 to 45.7)
MenY Before Vacc 1 >=1:6410.9 (7.5 to 15.3)11.2 (8.6 to 14.2)21.9 (16.6 to 28.0)20.2 (16.5 to 24.3)
MenY Before Vacc 1 >=1:1284.9 (2.6 to 8.2)6.3 (4.3 to 8.7)10.0 (6.4 to 14.8)10.5 (7.7 to 13.8)
MenY Before Vacc 2 >=1:4100.0 (98.5 to 100.0)98.9 (97.5 to 99.6)100.0 (98.2 to 100.0)99.5 (98.1 to 99.9)
MenY Before Vacc 2 >=1:8100.0 (98.5 to 100.0)97.2 (95.2 to 98.5)100.0 (98.2 to 100.0)99.5 (98.1 to 99.9)
MenY Before Vacc 2 >=1:1698.3 (95.8 to 99.5)92.9 (90.1 to 95.0)100.0 (98.2 to 100.0)99.2 (97.7 to 99.8)
MenY Before Vacc 2 >=1:3287.0 (82.1 to 91.0)77.1 (73.0 to 80.9)99.0 (96.4 to 99.9)95.8 (93.3 to 97.6)
MenY Before Vacc 2 >=1:6469.9 (63.6 to 75.6)56.2 (51.5 to 60.7)94.9 (90.9 to 97.6)88.5 (84.8 to 91.5)
MenY Before Vacc 2 >=1:12841.0 (34.7 to 47.5)31.1 (26.9 to 35.5)86.4 (80.8 to 90.8)80.6 (76.3 to 84.5)
SecondaryStage1: hSBA GMTs for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4

GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains. Titers below the LLOQ were set to 0.5\*LLOQ for analysis. Confidence intervals were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the concentrations, or the mean of the ratio.

Time frame:
Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Reported as:
Geometric mean · Titers
Stage1: hSBA GMTs for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4
TitersGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
MenA Before Vacc 15.7 (5.1 to 6.3)6.3 (5.7 to 6.8)11.0 (9.3 to 13.0)10.7 (9.6 to 12.0)
MenA Before Vacc 242.7 (36.1 to 50.4)47.2 (40.8 to 54.5)158.7 (132.6 to 189.8)214.6 (187.7 to 245.3)
MenC Before Vacc 17.5 (6.6 to 8.5)7.5 (6.8 to 8.2)11.9 (10.2 to 13.8)13.4 (11.9 to 15.1)
MenC Before Vacc 261.5 (49.5 to 76.3)32.7 (27.8 to 38.5)253.1 (213.0 to 300.8)186.7 (161.9 to 215.2)
MenW Before Vacc 17.0 (6.2 to 7.9)7.0 (6.4 to 7.5)10.5 (9.1 to 12.2)11.0 (9.8 to 12.3)
MenW Before Vacc 262.6 (53.5 to 73.1)39.1 (34.4 to 44.5)376.8 (311.4 to 456.0)255.5 (221.4 to 295.0)
MenY Before Vacc 110.5 (9.1 to 12.1)11.5 (10.4 to 12.7)19.2 (16.3 to 22.5)19.0 (16.8 to 21.4)
MenY Before Vacc 283.6 (71.4 to 97.8)58.6 (52.0 to 66.0)395.2 (327.8 to 476.3)264.0 (228.5 to 305.0)
SecondaryStage1: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

Time frame:
Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participantsGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22) Before Vacc 125.3 (21.2 to 29.7)25.1 (22.2 to 28.2)
PMB80 (A22) Before Vacc 241.6 (36.9 to 46.5)41.9 (38.6 to 45.3)
PMB2001 (A56) Before Vacc 113.8 (10.6 to 17.4)12.8 (10.6 to 15.3)
PMB2001 (A56) Before Vacc 252.2 (47.2 to 57.1)45.7 (42.3 to 49.2)
PMB2948 (B24) Before Vacc 110.4 (7.7 to 13.6)11.9 (9.8 to 14.3)
PMB2948 (B24) Before Vacc 226.5 (22.4 to 31.0)24.2 (21.3 to 27.2)
PMB2707 (B44) Before Vacc 13.7 (2.1 to 5.9)4.5 (3.2 to 6.1)
PMB2707 (B44) Before Vacc 218.8 (15.1 to 22.8)16.5 (14.0 to 19.2)
SecondaryStage1: Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for Each of the 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 for each of the 4 primary MenB test strains was reported in this outcome measure.

Time frame:
Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for Each of the 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participantsGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22) Before Vacc 1 >=1:434.7 (30.1 to 39.4)36.6 (33.3 to 40.0)
PMB80 (A22) Before Vacc 1 >=1:831.9 (27.5 to 36.5)31.8 (28.7 to 35.1)
PMB80 (A22) Before Vacc 1 >=1:1625.3 (21.2 to 29.7)25.1 (22.2 to 28.2)
PMB80 (A22) Before Vacc 1 >=1:3211.0 (8.2 to 14.4)11.4 (9.4 to 13.8)
PMB80 (A22) Before Vacc 1 >=1:644.7 (2.9 to 7.1)4.4 (3.1 to 6.0)
PMB80 (A22) Before Vacc 1 >=1:1281.4 (0.5 to 3.0)0.8 (0.3 to 1.7)
PMB80 (A22) Before Vacc 2 >=1:448.2 (43.4 to 53.1)49.8 (46.3 to 53.2)
PMB80 (A22) Before Vacc 2 >=1:844.5 (39.7 to 49.3)46.6 (43.1 to 50.0)
PMB80 (A22) Before Vacc 2 >=1:1641.6 (36.9 to 46.5)41.9 (38.6 to 45.3)
PMB80 (A22) Before Vacc 2 >=1:3223.5 (19.6 to 27.9)23.5 (20.7 to 26.5)
PMB80 (A22) Before Vacc 2 >=1:649.9 (7.2 to 13.1)9.0 (7.2 to 11.2)
PMB80 (A22) Before Vacc 2 >=1:1282.6 (1.3 to 4.6)3.2 (2.1 to 4.6)
PMB2001 (A56) Before Vacc 1 >=1:419.5 (15.8 to 23.6)17.5 (15.0 to 20.3)
PMB2001 (A56) Before Vacc 1 >=1:813.8 (10.6 to 17.4)12.8 (10.6 to 15.3)
PMB2001 (A56) Before Vacc 1 >=1:1610.7 (7.9 to 14.0)11.0 (9.0 to 13.4)
PMB2001 (A56) Before Vacc 1 >=1:326.7 (4.5 to 9.5)7.6 (5.9 to 9.6)
PMB2001 (A56) Before Vacc 1 >=1:643.8 (2.2 to 6.1)4.3 (3.0 to 5.9)
PMB2001 (A56) Before Vacc 1 >=1:1282.9 (1.5 to 4.9)2.4 (1.5 to 3.7)
PMB2001 (A56) Before Vacc 2 >=1:456.6 (51.6 to 61.4)50.6 (47.1 to 54.1)
PMB2001 (A56) Before Vacc 2 >=1:852.2 (47.2 to 57.1)45.7 (42.3 to 49.2)
PMB2001 (A56) Before Vacc 2 >=1:1647.1 (42.2 to 52.0)41.2 (37.8 to 44.7)
PMB2001 (A56) Before Vacc 2 >=1:3235.2 (30.6 to 40.0)30.9 (27.8 to 34.3)
PMB2001 (A56) Before Vacc 2 >=1:6421.4 (17.5 to 25.6)19.0 (16.3 to 21.9)
PMB2001 (A56) Before Vacc 2 >=1:12810.0 (7.2 to 13.3)9.5 (7.6 to 11.7)
PMB2948 (B24) Before Vacc 1 >=1:414.1 (10.9 to 17.7)14.6 (12.3 to 17.2)
PMB2948 (B24) Before Vacc 1 >=1:810.4 (7.7 to 13.6)11.9 (9.8 to 14.3)
PMB2948 (B24) Before Vacc 1 >=1:166.2 (4.1 to 8.9)8.2 (6.4 to 10.2)
PMB2948 (B24) Before Vacc 1 >=1:323.7 (2.1 to 5.9)4.2 (3.0 to 5.8)
PMB2948 (B24) Before Vacc 1 >=1:640.9 (0.3 to 2.3)2.3 (1.4 to 3.6)
PMB2948 (B24) Before Vacc 1 >=1:1280.2 (0.0 to 1.3)1.1 (0.5 to 2.0)
PMB2948 (B24) Before Vacc 2 >=1:430.5 (26.1 to 35.1)28.0 (25.0 to 31.2)
PMB2948 (B24) Before Vacc 2 >=1:826.5 (22.4 to 31.0)24.2 (21.3 to 27.2)
PMB2948 (B24) Before Vacc 2 >=1:1621.4 (17.6 to 25.6)20.2 (17.5 to 23.0)
PMB2948 (B24) Before Vacc 2 >=1:3211.2 (8.3 to 14.5)11.0 (9.0 to 13.3)
PMB2948 (B24) Before Vacc 2 >=1:645.1 (3.2 to 7.6)5.7 (4.2 to 7.5)
PMB2948 (B24) Before Vacc 2 >=1:1282.3 (1.1 to 4.2)2.3 (1.4 to 3.5)
PMB2707 (B44) Before Vacc 1 >=1:47.1 (4.9 to 10.0)7.2 (5.6 to 9.1)
PMB2707 (B44) Before Vacc 1 >=1:83.7 (2.1 to 5.9)4.5 (3.2 to 6.1)
PMB2707 (B44) Before Vacc 1 >=1:162.1 (1.0 to 3.9)3.3 (2.2 to 4.7)
PMB2707 (B44) Before Vacc 1 >=1:320.9 (0.3 to 2.3)2.1 (1.2 to 3.3)
PMB2707 (B44) Before Vacc 1 >=1:640.7 (0.1 to 2.0)1.2 (0.6 to 2.1)
PMB2707 (B44) Before Vacc 1 >=1:1280.5 (0.1 to 1.7)0.3 (0.1 to 1.0)
PMB2707 (B44) Before Vacc 2 >=1:429.2 (24.9 to 33.8)25.7 (22.8 to 28.8)
PMB2707 (B44) Before Vacc 2 >=1:818.8 (15.1 to 22.8)16.5 (14.0 to 19.2)
PMB2707 (B44) Before Vacc 2 >=1:1613.5 (10.4 to 17.2)11.7 (9.6 to 14.1)
PMB2707 (B44) Before Vacc 2 >=1:327.6 (5.3 to 10.6)5.8 (4.3 to 7.6)
PMB2707 (B44) Before Vacc 2 >=1:643.3 (1.8 to 5.5)2.8 (1.8 to 4.2)
PMB2707 (B44) Before Vacc 2 >=1:1280.7 (0.1 to 2.1)1.4 (0.7 to 2.5)
SecondaryStage1: hSBA GMTs for Each of the 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)

GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ =1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5\*LLOQ for analysis. CIs were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the hSBA titers.

Time frame:
Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Reported as:
Geometric mean · Titers
Stage1: hSBA GMTs for Each of the 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
TitersGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22), Before vacc 110.8 (10.2 to 11.5)10.7 (10.3 to 11.1)
PMB80 (A22), Before vacc 213.7 (12.8 to 14.8)13.8 (13.1 to 14.5)
PMB2001 (A56), Before vacc 15.2 (4.9 to 5.7)5.3 (5.0 to 5.6)
PMB2001 (A56), Before vacc 213.0 (11.4 to 14.8)11.4 (10.4 to 12.5)
PMB2948 (B24), Before vacc 14.6 (4.4 to 4.9)4.9 (4.7 to 5.1)
PMB2948 (B24), Before vacc 26.3 (5.8 to 6.9)6.2 (5.9 to 6.6)
PMB2707 (B44), Before vacc 14.2 (4.1 to 4.4)4.3 (4.2 to 4.5)
PMB2707 (B44), Before vacc 25.4 (5.1 to 5.8)5.3 (5.0 to 5.5)
SecondaryStage2: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or LLOQ if Higher) for ACWY Test Strains During Persistence Phase: Groups 1, 2, 3 and 4

Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY Test Strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.

Time frame:
12, 24, 36 and 48 months after Vaccination 2 (Vacc 2)
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or LLOQ if Higher) for ACWY Test Strains During Persistence Phase: Groups 1, 2, 3 and 4
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
MenA 12 Months after Vacc 291.1 (84.2 to 95.6)71.2 (57.9 to 82.2)97.9 (88.9 to 99.9)100.0 (84.6 to 100.0)
MenA 24 Months after Vacc 288.1 (80.2 to 93.7)70.0 (56.8 to 81.2)100.0 (94.1 to 100.0)100.0 (90.5 to 100.0)
MenA 36 Months after Vacc 288.4 (80.2 to 94.1)72.2 (58.4 to 83.5)100.0 (93.7 to 100.0)97.0 (84.2 to 99.9)
MenA 48 Months after Vacc 281.7 (70.7 to 89.9)63.4 (46.9 to 77.9)100.0 (91.2 to 100.0)100.0 (85.2 to 100.0)
MenC 12 Months after Vacc 276.8 (67.9 to 84.2)51.6 (38.6 to 64.5)96.3 (87.3 to 99.5)91.3 (72.0 to 98.9)
MenC 24 Months after Vacc 275.2 (65.7 to 83.3)47.5 (34.6 to 60.7)96.9 (91.2 to 99.4)94.4 (86.2 to 98.4)
MenC 36 Months after Vacc 267.4 (57.0 to 76.6)44.4 (30.9 to 58.6)96.9 (91.1 to 99.4)95.5 (87.5 to 99.1)
MenC 48 Months after Vacc 262.0 (49.7 to 73.2)38.1 (23.6 to 54.4)98.7 (92.9 to 100.0)89.7 (78.8 to 96.1)
MenW 12 Months after Vacc 299.1 (95.1 to 100.0)83.9 (72.3 to 92.0)100.0 (92.6 to 100.0)95.5 (77.2 to 99.9)
MenW 24 Months after Vacc 299.0 (94.7 to 100.0)78.7 (66.3 to 88.1)100.0 (94.1 to 100.0)94.6 (81.8 to 99.3)
MenW 36 Months after Vacc 294.8 (88.4 to 98.3)77.8 (64.4 to 88.0)100.0 (93.7 to 100.0)97.0 (84.2 to 99.9)
MenW 48 Months after Vacc 291.4 (82.3 to 96.8)70.7 (54.5 to 83.9)100.0 (91.2 to 100.0)91.3 (72.0 to 98.9)
MenY 12 Months after Vacc 2100.0 (96.8 to 100.0)98.4 (91.3 to 100.0)100.0 (92.6 to 100.0)100.0 (84.6 to 100.0)
MenY 24 Months after Vacc 2100.0 (96.4 to 100.0)93.4 (84.1 to 98.2)100.0 (94.1 to 100.0)100.0 (90.5 to 100.0)
MenY 36 Months after Vacc 2100.0 (96.3 to 100.0)90.7 (79.7 to 96.9)100.0 (93.7 to 100.0)100.0 (84.2 to 100.0)
MenY 48 Months after Vacc 2100.0 (94.9 to 100.0)95.2 (83.8 to 99.4)100.0 (91.2 to 100.0)100.0 (84.6 to 100.0)
SecondaryStage2: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains During Persistence Phase (Group 1 and 3 Combined; Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

Time frame:
12, 24, 36 and 48 months after Vaccination 2 (Vacc 2)
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains During Persistence Phase (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participantsGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22) 12 months after Vacc 232.7 (25.6 to 40.5)26.5 (17.4 to 37.3)
PMB80 (A22) 24 months after Vacc 236.7 (30.0 to 43.9)28.9 (21.2 to 37.6)
PMB80 (A22) 36 months after Vacc 229.2 (22.8 to 36.3)25.9 (18.2 to 34.8)
PMB80 (A22) 48 months after Vacc 228.1 (20.8 to 36.3)31.9 (22.7 to 42.3)
PMB2001 (A56) 12 months after Vacc 233.3 (26.1 to 41.2)32.1 (22.4 to 43.2)
PMB2001 (A56) 24 months after Vacc 234.7 (28.1 to 41.8)33.6 (25.6 to 42.4)
PMB2001 (A56) 36 months after Vacc 229.0 (22.6 to 36.1)33.9 (25.4 to 43.2)
PMB2001 (A56) 48 months after Vacc 234.5 (26.8 to 42.8)29.6 (20.8 to 39.7)
PMB2948 (B24) 12 months after Vacc 230.9 (24.0 to 38.6)28.2 (19.0 to 39.0)
PMB2948 (B24) 24 months after Vacc 233.2 (26.6 to 40.2)27.5 (20.0 to 36.0)
PMB2948 (B24) 36 months after Vacc 235.4 (28.7 to 42.6)28.3 (20.5 to 37.3)
PMB2948 (B24) 48 months after Vacc 236.6 (28.7 to 44.9)26.5 (18.1 to 36.4)
PMB2707 (B44) 12 months after Vacc 218.7 (13.1 to 25.4)15.3 (8.4 to 24.7)
PMB2707 (B44) 24 months after Vacc 218.0 (12.9 to 24.0)18.2 (12.0 to 25.8)
PMB2707 (B44) 36 months after Vacc 220.2 (14.8 to 26.6)19.8 (13.1 to 28.1)
PMB2707 (B44) 48 months after Vacc 218.2 (12.4 to 25.4)16.2 (9.5 to 24.9)
SecondaryStage2: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or >=LLOQ if Higher) for ACWY Test Strains 1 Month After Booster Vaccination: Groups 1 and 3 (Separately)

Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure. Analysis was planned for Group 1 and 3 separately.

Time frame:
1 month after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or >=LLOQ if Higher) for ACWY Test Strains 1 Month After Booster Vaccination: Groups 1 and 3 (Separately)
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
MenA100.0 (94.0 to 100.0)100.0 (89.4 to 100.0)
MenC100.0 (94.0 to 100.0)100.0 (94.9 to 100.0)
MenW100.0 (94.0 to 100.0)100.0 (89.4 to 100.0)
MenY100.0 (94.0 to 100.0)100.0 (89.4 to 100.0)
SecondaryStage2: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains 1 Month After Booster Vaccination (Group 1 and 3 Combined; Group 2 and 4 Combined)

Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.

Time frame:
1 month after booster vaccination
Reported as:
Number · Percentage of participants
Stage2: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains 1 Month After Booster Vaccination (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participantsGroup 1+3 Combined (MenABCWY + Saline)Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)
PMB80 (A22)95.1 (89.6 to 98.2)93.8 (86.2 to 98.0)
PMB2001 (A56)100.0 (97.1 to 100.0)98.8 (93.7 to 100.0)
PMB2948 (B24)95.1 (89.7 to 98.2)95.2 (88.3 to 98.7)
PMB2707 (B44)99.2 (95.7 to 100.0)98.8 (93.7 to 100.0)
SecondaryStage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1: Group 1 and Group 3

Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
7 days after Vaccination 1 (Vacc 1)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Redness: Any19.7 (15.1 to 25.0)14.9 (10.8 to 19.7)
Redness: Mild7.4 (4.6 to 11.2)5.6 (3.2 to 9.0)
Redness: Moderate10.0 (6.7 to 14.3)7.4 (4.6 to 11.2)
Redness: Severe2.2 (0.8 to 4.8)1.9 (0.6 to 4.3)
Swelling: Any20.8 (16.1 to 26.2)17.5 (13.1 to 22.5)
Swelling: Mild9.3 (6.1 to 13.4)8.6 (5.5 to 12.6)
Swelling: Moderate10.4 (7.0 to 14.7)8.6 (5.5 to 12.6)
Swelling: Severe1.1 (0.2 to 3.2)0.4 (0.0 to 2.1)
Pain at injection site: Any89.2 (84.9 to 92.7)90.3 (86.2 to 93.6)
Pain at injection site: Mild37.2 (31.4 to 43.3)45.4 (39.3 to 51.5)
Pain at injection site: Moderate45.7 (39.7 to 51.9)40.1 (34.2 to 46.3)
Pain at injection site: Severe6.3 (3.7 to 9.9)4.8 (2.6 to 8.1)
SecondaryStage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2: Group 1 and Group 3

Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
7 days after Vaccination 2 (Vacc 2)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Redness: Any23.0 (17.8 to 29.0)19.3 (14.4 to 25.0)
Redness: Mild7.0 (4.0 to 11.1)6.9 (4.0 to 10.9)
Redness: Moderate11.7 (7.9 to 16.6)9.0 (5.7 to 13.4)
Redness: Severe4.3 (2.1 to 7.9)3.4 (1.5 to 6.7)
Swelling: Any19.1 (14.3 to 24.8)18.0 (13.3 to 23.6)
Swelling: Mild8.7 (5.4 to 13.1)5.6 (3.0 to 9.4)
Swelling: Moderate10.0 (6.4 to 14.6)11.2 (7.4 to 15.9)
Swelling: Severe0.4 (0.0 to 2.4)1.3 (0.3 to 3.7)
Pain at injection site: Any85.2 (80.0 to 89.5)83.7 (78.3 to 88.2)
Pain at injection site: Mild34.3 (28.2 to 40.9)37.8 (31.5 to 44.3)
Pain at injection site: Moderate47.0 (40.4 to 53.6)38.2 (31.9 to 44.8)
Pain at injection site: Severe3.9 (1.8 to 7.3)7.7 (4.6 to 11.9)
SecondaryStage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1: Group 1 and Group 3

Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

Time frame:
7 days after Vaccination 1 (Vacc 1)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Fever: >= 38.0 degree C7.4 (4.6 to 11.2)5.2 (2.9 to 8.6)
Fever: 38.0 to 38.4 degree C4.1 (2.1 to 7.2)4.1 (2.1 to 7.2)
Fever: 38.4 to 38.9 degree C2.2 (0.8 to 4.8)0.7 (0.1 to 2.7)
Fever: 38.9 to 40.0 degree C1.1 (0.2 to 3.2)0.4 (0.0 to 2.1)
Fever: > 40.0 degree C0.0 (0.0 to 1.4)0.0 (0.0 to 1.4)
Fatigue: Any56.5 (50.4 to 62.5)49.1 (42.9 to 55.2)
Fatigue: Mild26.8 (21.6 to 32.5)27.9 (22.6 to 33.6)
Fatigue: Moderate25.3 (20.2 to 30.9)17.5 (13.1 to 22.5)
Fatigue: Severe4.5 (2.3 to 7.7)3.7 (1.8 to 6.7)
Headache: Any48.3 (42.2 to 54.5)45.0 (38.9 to 51.1)
Headache: Mild27.1 (21.9 to 32.9)29.4 (24.0 to 35.2)
Headache: Moderate19.3 (14.8 to 24.6)14.1 (10.2 to 18.9)
Headache: Severe1.9 (0.6 to 4.3)1.5 (0.4 to 3.8)
Chills: Any20.1 (15.5 to 25.4)14.9 (10.8 to 19.7)
Chills: Mild14.5 (10.5 to 19.3)9.3 (6.1 to 13.4)
Chills: Moderate4.5 (2.3 to 7.7)4.8 (2.6 to 8.1)
Chills: Severe1.1 (0.2 to 3.2)0.7 (0.1 to 2.7)
Vomiting: Any2.6 (1.1 to 5.3)1.9 (0.6 to 4.3)
Vomiting: Mild2.2 (0.8 to 4.8)1.9 (0.6 to 4.3)
Vomiting: Moderate0.4 (0.0 to 2.1)0.0 (0.0 to 1.4)
Vomiting: severe0.0 (0.0 to 1.4)0.0 (0.0 to 1.4)
Diarrhea: Any12.3 (8.6 to 16.8)15.2 (11.2 to 20.1)
Diarrhea: Mild10.0 (6.7 to 14.3)10.8 (7.3 to 15.1)
Diarrhea: Moderate2.2 (0.8 to 4.8)4.5 (2.3 to 7.7)
Diarrhea: Severe0.0 (0.0 to 1.4)0.0 (0.0 to 1.4)
Muscle pain: Any29.0 (23.6 to 34.8)22.7 (17.8 to 28.2)
Muscle pain: Mild17.1 (12.8 to 22.1)14.5 (10.5 to 19.3)
Muscle pain: Moderate10.4 (7.0 to 14.7)7.1 (4.3 to 10.8)
Muscle pain: Severe1.5 (0.4 to 3.8)1.1 (0.2 to 3.2)
Joint pain: Any20.8 (16.1 to 26.2)18.2 (13.8 to 23.4)
Joint pain: Mild13.0 (9.2 to 17.6)10.8 (7.3 to 15.1)
Joint pain: Moderate7.8 (4.9 to 11.7)6.7 (4.0 to 10.4)
Joint pain: Severe0.0 (0.0 to 1.4)0.7 (0.1 to 2.7)
SecondaryStage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2: Group 1 and Group 3

Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).

Time frame:
7 days after Vaccination 2 (Vacc 2)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Fever: >= 38.0 degree C3.5 (1.5 to 6.7)1.7 (0.5 to 4.3)
Fever: 38.0 to 38.4°C2.2 (0.7 to 5.0)0.9 (0.1 to 3.1)
Fever: 38.5 to 38.9°C1.3 (0.3 to 3.8)0.9 (0.1 to 3.1)
Fever: 39.0 to 40.0°C0.0 (0.0 to 1.6)0.0 (0.0 to 1.6)
Fever: > 40.0°C0.0 (0.0 to 1.6)0.0 (0.0 to 1.6)
Fatigue: Any49.6 (42.9 to 56.2)47.6 (41.1 to 54.3)
Fatigue: Mild20.9 (15.8 to 26.7)26.2 (20.7 to 32.3)
Fatigue: Moderate26.1 (20.5 to 32.3)18.9 (14.1 to 24.5)
Fatigue: Severe2.6 (1.0 to 5.6)2.6 (1.0 to 5.5)
Headache: Any41.7 (35.3 to 48.4)43.8 (37.3 to 50.4)
Headache: Mild22.6 (17.4 to 28.6)26.6 (21.1 to 32.8)
Headache: Moderate17.8 (13.1 to 23.4)13.3 (9.2 to 18.4)
Headache: Severe1.3 (0.3 to 3.8)3.9 (1.8 to 7.2)
Chills: Any20.9 (15.8 to 26.7)19.3 (14.4 to 25.0)
Chills: Mild16.1 (11.6 to 21.5)11.6 (7.8 to 16.4)
Chills: Moderate3.9 (1.8 to 7.3)5.2 (2.7 to 8.8)
Chills: Severe0.9 (0.1 to 3.1)2.6 (1.0 to 5.5)
Vomiting: Any1.7 (0.5 to 4.4)3.9 (1.8 to 7.2)
Vomiting: Mild1.7 (0.5 to 4.4)3.4 (1.5 to 6.7)
Vomiting: Moderate0.0 (0.0 to 1.6)0.4 (0.0 to 2.4)
Vomiting: Severe0.0 (0.0 to 1.6)0.0 (0.0 to 1.6)
Diarrhea: Any13.5 (9.3 to 18.6)8.2 (5.0 to 12.4)
Diarrhea: Mild9.6 (6.1 to 14.1)5.2 (2.7 to 8.8)
Diarrhea: Moderate3.9 (1.8 to 7.3)2.6 (1.0 to 5.5)
Diarrhea: Severe0.0 (0.0 to 1.6)0.4 (0.0 to 2.4)
Muscle pain: Any24.8 (19.3 to 30.9)19.3 (14.4 to 25.0)
Muscle pain: Mild13.0 (9.0 to 18.1)8.6 (5.3 to 12.9)
Muscle pain: Moderate10.9 (7.2 to 15.6)9.9 (6.4 to 14.4)
Muscle pain: Severe0.9 (0.1 to 3.1)0.9 (0.1 to 3.1)
Joint pain: Any18.7 (13.9 to 24.3)18.0 (13.3 to 23.6)
Joint pain: Mild9.1 (5.7 to 13.6)10.7 (7.1 to 15.4)
Joint pain: Moderate9.1 (5.7 to 13.6)6.4 (3.6 to 10.4)
Joint pain: Severe0.4 (0.0 to 2.4)0.9 (0.1 to 3.1)
SecondaryStage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 1: Group 1 and Group 3
Time frame:
30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 1: Group 1 and Group 320.8 (16.1 to 26.2)13.8 (9.9 to 18.5)
SecondaryStage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 2: Group 1 and Group 3
Time frame:
30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 2: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 2: Group 1 and Group 317.8 (13.1 to 23.4)13.3 (9.2 to 18.4)
SecondaryStage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 1: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 1: Group 1 and Group 30.0 (0.0 to 1.3)0.7 (0.1 to 2.6)
SecondaryStage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 2: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 2: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 2: Group 1 and Group 30.4 (0.0 to 2.3)0.0 (0.0 to 1.5)
SecondaryStage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
30 days after any vaccination
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination: Group 1 and Group 30.4 (0.0 to 2.0)0.7 (0.1 to 2.6)
SecondaryStage1: Percentage of Participants With at Least 1 SAE During the Vaccination Phase: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE During the Vaccination Phase: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 SAE During the Vaccination Phase: Group 1 and Group 30.4 (0.0 to 2.0)1.8 (0.6 to 4.3)
SecondaryStage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.

Time frame:
Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase: Group 1 and Group 30.8 (0.1 to 3.0)0.4 (0.0 to 2.3)
SecondaryStage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.

Time frame:
Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1: Group 1 and Group 31.5 (0.4 to 3.7)2.2 (0.8 to 4.8)
SecondaryStage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1: Group 1 and Group 3

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 days after vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1: Group 1 and Group 34.8 (2.6 to 8.0)5.9 (3.4 to 9.4)
SecondaryStage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2: Group 1 and Group 3

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 days after vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2: Group 1 and Group 35.8 (3.2 to 9.5)9.0 (5.7 to 13.3)
SecondaryStage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination: Group 1 and Group 3

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 days after any vaccination
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination: Group 1 and Group 39.6 (6.3 to 13.7)13.3 (9.5 to 17.9)
SecondaryStage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase: Group 1 and Group 3

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase: Group 1 and Group 323.9 (19.0 to 29.4)28.4 (23.1 to 34.2)
SecondaryStage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase: Group 1 and Group 3

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase: Group 1 and Group 313.8 (9.7 to 18.8)18.8 (14.1 to 24.4)
SecondaryStage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1: Group 1 and Group 3

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1: Group 1 and Group 330.9 (25.4 to 36.7)35.1 (29.4 to 41.1)
SecondaryStage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 1: Group 1 and Group 3

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
30 days after vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 1: Group 1 and Group 30.0 (0.0 to 1.3)0.0 (0.0 to 1.4)
SecondaryStage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 2: Group 1 and Group 3

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
30 days after vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 2: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 2: Group 1 and Group 30.0 (0.0 to 1.5)0.0 (0.0 to 1.5)
SecondaryStage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Any Vaccination: Group 1 and Group 3

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
30 days after any vaccination
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Any Vaccination: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Any Vaccination: Group 1 and Group 30.0 (0.0 to 1.3)0.0 (0.0 to 1.4)
SecondaryStage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Vaccination Phase: Group 1 and Group 3

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Vaccination Phase: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Vaccination Phase: Group 1 and Group 30.7 (0.1 to 2.6)0.0 (0.0 to 1.4)
SecondaryStage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Follow-up Phase: Group 1 and Group 3

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Follow-up Phase: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Follow-up Phase: Group 1 and Group 30.4 (0.0 to 2.3)0.0 (0.0 to 1.5)
SecondaryStage1: Percentage of Participants With at Least 1 NDCMC Throughout the Stage 1: Group 1 and Group 3

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 NDCMC Throughout the Stage 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 NDCMC Throughout the Stage 1: Group 1 and Group 31.1 (0.2 to 3.2)0.0 (0.0 to 1.4)
SecondaryStage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
30 days after vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1: Group 1 and Group 315.1 (11.0 to 19.9)11.1 (7.6 to 15.4)
SecondaryStage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
30 days after vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2: Group 1 and Group 316.1 (11.7 to 21.4)12.3 (8.5 to 17.1)
SecondaryStage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination Any Vaccination: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
30 days after any vaccination
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination Any Vaccination: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination Any Vaccination: Group 1 and Group 325.7 (20.6 to 31.4)19.9 (15.3 to 25.2)
SecondaryStage1: Percentage of Participants With at Least 1 AE During the Stage 1 Vaccination Phase: Group 1 and Group 3

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.

Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 AE During the Stage 1 Vaccination Phase: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 AE During the Stage 1 Vaccination Phase: Group 1 and Group 341.5 (35.6 to 47.6)36.9 (31.1 to 42.9)
SecondaryStage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1: Group 1 and Group 3

Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

Time frame:
30 minutes after Vaccination 1
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1: Group 1 and Group 30.0 (0.0 to 1.3)0.0 (0.0 to 1.4)
SecondaryStage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2: Group 1 and Group 3

Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.

Time frame:
30 minutes after Vaccination 2
Reported as:
Number · Percentage of participants
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2: Group 1 and Group 3
Percentage of participantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2: Group 1 and Group 30.0 (0.0 to 1.5)0.0 (0.0 to 1.5)
SecondaryStage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase: Group 1 and Group 3
Time frame:
Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Reported as:
Count of participants · Participants
Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase: Group 1 and Group 3
ParticipantsGroup 1: MenABCWY + Saline (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)
Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase: Group 1 and Group 33846

Adverse events

Collected over Systematic assessment: Local reactions and systemic events recorded within 7 days of each vaccination; Non-systematic collection: SAEs recorded from Month 0 to 6 months after Vaccination 2 (up to Month 12) and 6 months after Booster Vaccination (Booster Vaccination was at Month 54); Non-SAEs recorded from Month 0 to 1 month after Vaccination 2 ( up to Month 7); within 48 hours of blood draw at Month 18, 30 and 42; and 1 month after Booster Vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1: Group 1: MenABCWY + Saline (ACWY-Naive)1/272 (0.4%)5/272 (1.8%)267/272 (98.2%)
Stage 1: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)0/534 (0%)6/534 (1.1%)508/534 (95.1%)
Stage 1: Group 3: MenABCWY + Saline (ACWY-Experienced)0/271 (0%)6/271 (2.2%)259/271 (95.6%)
Stage 1: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)0/523 (0%)9/523 (1.7%)502/523 (96%)
Stage 2: Group 1: MenABCWY + Saline (ACWY-Naive)0/114 (0%)1/114 (0.9%)54/114 (47.4%)
Stage 2: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)0/65 (0%)1/65 (1.5%)37/65 (56.9%)
Stage 2: Group 3: MenABCWY + Saline (ACWY-Experienced)0/101 (0%)3/101 (3%)72/101 (71.3%)
Stage 2: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)0/73 (0%)2/73 (2.7%)57/73 (78.1%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventStage 1: Group 1: MenABCWY + Saline (ACWY-Naive)Stage 1: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Stage 1: Group 3: MenABCWY + Saline (ACWY-Experienced)Stage 1: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Stage 2: Group 1: MenABCWY + Saline (ACWY-Naive)Stage 2: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Stage 2: Group 3: MenABCWY + Saline (ACWY-Experienced)Stage 2: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Femur fractureInjury, poisoning and procedural complications0/2720/5340/2710/5230/1140/652/1010/73
Major depressionPsychiatric disorders0/2720/5340/2711/5230/1141/650/1010/73
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2720/5340/2710/5231/1140/651/1011/73
Psychotic disorderPsychiatric disorders0/2720/5340/2710/5230/1140/650/1011/73
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2721/5340/2710/5230/1140/651/1010/73
Suicidal ideationPsychiatric disorders0/2720/5342/2710/5230/1140/650/1010/73
OverdoseInjury, poisoning and procedural complications0/2720/5341/2710/5230/1140/650/1010/73
Tendon injuryInjury, poisoning and procedural complications0/2720/5341/2710/5230/1140/650/1010/73
DyskinesiaNervous system disorders0/2720/5341/2710/5230/1140/650/1010/73
Migraine with auraNervous system disorders0/2720/5341/2710/5230/1140/650/1010/73
Most frequent other events
Showing 10 of 71
Most frequent other events
EventStage 1: Group 1: MenABCWY + Saline (ACWY-Naive)Stage 1: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Stage 1: Group 3: MenABCWY + Saline (ACWY-Experienced)Stage 1: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Stage 2: Group 1: MenABCWY + Saline (ACWY-Naive)Stage 2: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Stage 2: Group 3: MenABCWY + Saline (ACWY-Experienced)Stage 2: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)
Injection site pain (PAIN AT INJECTION SITE)General disorders256/272479/534251/271480/52348/11434/6565/10150/73
FatigueGeneral disorders180/272315/534163/271344/52328/11424/6547/10137/73
HeadacheNervous system disorders163/272312/534159/271312/52323/11421/6535/10131/73
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders104/272204/53487/271186/52311/11412/6524/10113/73
ChillsGeneral disorders82/272152/53467/271141/5236/1147/6514/1018/73
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders79/272153/53478/271148/52312/11410/6516/1019/73
SwellingGeneral disorders77/272123/53467/271114/52311/1149/6514/10110/73
Erythema (REDNESS)Skin and subcutaneous tissue disorders73/272130/53461/27195/5238/11411/6516/10114/73
Diarrhoea (DIARRHEA)Gastrointestinal disorders55/272104/53454/271105/5233/1144/657/1017/73
Pyrexia (FEVER)General disorders29/27256/53417/27137/5233/1141/650/1011/73

Baseline characteristics

The safety population for Stage 1 included participants who had received at least 1 dose of investigational product during Stage 1 and for whom safety data were available.

Age, Continuous
Age, Continuous(Years)Group 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Total
Stage 116.0 ± 5.6716.5 ± 5.8117.7 ± 3.5717.8 ± 3.6617.1 ± 4.87
Stage 219.1 ± 5.3618.5 ± 5.5120.8 ± 3.7321.1 ± 4.1120.4 ± 4.72
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Total
Stage 1 — Female144333152289918
Stage 1 — Male128201119234682
Stage 2 — Female28264729130
Stage 2 — Male39143027110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Total
Stage 1 — Hispanic or Latino35732461193
Stage 1 — Not Hispanic or Latino2364612464611404
Stage 1 — Unknown or Not Reported10113
Stage 2 — Hispanic or Latino633113
Stage 2 — Not Hispanic or Latino61377455227
Stage 2 — Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: MenABCWY + Saline (ACWY-Naive)Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive)Group 3: MenABCWY + Saline (ACWY-Experienced)Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced)Total
Stage 1 — American Indian or Alaska Native101362049
Stage 1 — Asian143816
Stage 1 — Native Hawaiian or Other Pacific Islander00000
Stage 1 — Black or African American27532560165
Stage 1 — White2344642374351370
Stage 1 — More than one race00000
Stage 1 — Unknown or Not Reported00000
Stage 2 — American Indian or Alaska Native00000
Stage 2 — Asian00011
Stage 2 — Native Hawaiian or Other Pacific Islander00000
Stage 2 — Black or African American534214
Stage 2 — White59377253221
Stage 2 — More than one race00000
Stage 2 — Unknown or Not Reported30104
08

Study locations

75 sites
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35205, United States
  • Optimal Research, LLC
    Huntsville, Alabama 35802, United States
  • Synexus Clinical Research US, Inc./Fountain Hills Family Practice, P.C.
    Fountain Hills, Arizona 85268, United States
  • Clinical Research Consortium
    Tempe, Arizona 85283, United States
  • Harrisburg Family Medical Center
    Harrisburg, Arkansas 72432, United States
  • Paradigm Clinical Research Centers, Inc.
    La Mesa, California 91942, United States
  • California Research Foundation
    San Diego, California 92123, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Optimal Research, LLC
    Melbourne, Florida 32934, United States
  • Meridian Clinical Research LLC
    Savannah, Georgia 31406, United States
  • Optimal Research
    Peoria, Illinois 61614, United States
  • Meridian Clinical Research
    Sioux City, Iowa 51106, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • Alliance For Multispecialty Research (AMR)
    Wichita, Kansas 67207, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • Horizon Research Group of Opelousas, LLC
    Eunice, Louisiana 70535, United States
  • ACC Pediatric Research
    Haughton, Louisiana 71037, United States
  • Methodist Physicians Clinic/CCT Research
    Fremont, Nebraska 68025, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Meridian Clinical Research, LLC
    Binghamton, New York 13901, United States
  • United Medical Associates
    Binghamton, New York 13901, United States
  • Meridian Clinical Research, LLC
    Binghamton, New York 13905, United States
  • United Medical Associates
    Binghamton, New York 13905, United States
  • Regional Clinical Research, Inc
    Endwell, New York 13760, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Meridian Clinical Research, LLC
    Vestal, New York 13850, United States
  • Regional Clinical Research, Inc
    Vestal, New York 13850, United States
  • Capitol Pediatrics & Adolescent Center PLLC
    Raleigh, North Carolina 27609, United States
  • Meridian Clinical Research, LLC
    Cincinnati, Ohio 45246, United States
  • Velocity Clinical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Aventiv Research Inc.
    Columbus, Ohio 43213, United States
  • Ohio Pediatric Research Association, Inc.
    Dayton, Ohio 45414, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Liberty Family Practice
    Erie, Pennsylvania 16508, United States
  • Charleston Pediatrics, PA
    Charleston, South Carolina 29403, United States
  • PMG Research of Charleston, LLC
    Mount Pleasant, South Carolina 29464, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Internal Medicine and Pediatric Associates of Bristol, PC
    Bristol, Tennessee 37620, United States
  • PMG Research of Bristol, LLC
    Bristol, Tennessee 37620, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Texas Health Care, PLLC
    Fort Worth, Texas 76104, United States
  • Ventavia Research Group, LLC
    Fort Worth, Texas 76104, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • Acrc Trials
    Plano, Texas 75024, United States
  • North Texas Family Medicine
    Plano, Texas 75093, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • J. Lewis Research Inc. / Foothill Family Clinic Draper
    Draper, Utah 84020, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • J. Lewis Research, Inc. / Jordan River Family Medicine
    South Jordan, Utah 84095, United States
  • PI-Coor Clinical Research, LLC
    Burke, Virginia 22015, United States
  • Pediatric Research of Charlottesville, LLC
    Charlottesville, Virginia 22902, United States
  • Ordinace praktickeho lekare pro deti a dorost
    Jindrichuv Hradec, 377 01, Czechia
  • MEDICENTRUM 6 s.r.o. - Ordinace praktickeho lekare pro deti a dorost
    Praha 6, 160 00, Czechia
  • Espoo Vaccine Research Clinic
    Espoo, 02230, Finland
  • Helsinki South Vaccine Research Clinic
    Helsinki, 00100, Finland
  • Helsinki East Vaccine Research Clinic
    Helsinki, 00930, Finland
  • Jarvenpaa Vaccine Research Clinic
    Järvenpää, 04400, Finland
  • Kokkola Vaccine Research Clinic
    Kokkola, 67100, Finland
  • Oulu Vaccine Research Clinic
    Oulu, 90220, Finland
  • Pori Vaccine Research Clinic
    Pori, 28100, Finland
  • Seinajoki Vaccine Research Clinic
    Seinajoki, 60100, Finland
  • Tampere Vaccine Research Clinic
    Tampere, 33100, Finland
  • Turku Vaccine Research Clinic
    Turku, 20520, Finland
  • Jerzy Brzostek Prywatny Gabinet Lekarski
    Debica, 39-200, Poland
  • Hanna Czajka Indywidualna Specjalistyczna Praktyka Lekarska
    Krakow, 30-348, Poland
  • Oddzial Pediatrii i Neurologii Dzieciecej, Krakowski Szpital Specjalistyczny im. Jana Pawla II
    Krakow, 31-202, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Oct 2022, 66 months.

Results were first posted in Aug 2023, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2017
First posted
May 1, 2017
StartActual
Apr 24, 2017
Primary completionActual
Oct 25, 2022
CompletionActual
Oct 25, 2022
Results first posted
Aug 8, 2023
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03135834
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 1, 2017
Start date
Apr 24, 2017
Primary completion
Oct 25, 2022
Completion
Oct 25, 2022
Results posted
Aug 8, 2023
Last update
Aug 8, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meningococcal pentavalent vaccine · MenB-FHbp vaccine · 4CMenB vaccine

Start the discussion